Regulation of Vitamin C Transport in Brain by Pierce, Marquicia Reginee
 REGULATION OF VITAMIN C TRANSPORT IN BRAIN 
By 
 
Marquicia Regineé Pierce 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
in 
 
Molecular Physiology & Biophysics 
May 2014 
Nashville, TN 
 
Approved: 
 
 
Charles Cobb, PhD 
 
Roger Colbran, PhD 
 
Aurelio Galli, PhD 
 
Kristina Hill, PhD 
 
Danny Winder, PhD 
ii 
DEDICATION 
 
 
To God and Family: 
 
 
Especially my parents, Mark & Regina,  
for being such a beautiful example of faith, love and strength 
 
And to my siblings, Renyshia, Mark II and Edwin 
 
Dr. Sarah M. Johnson & M. Jean Springs, 
Thank you for being there every step of the way 
 
 
  
iii 
ACKNOWLEDGEMENTS 
 
It is with a grateful heart that I acknowledge the many people who have made this dissertation 
possible. 
 
First, I would like to thank my mentor, Dr. James May for granting me the opportunity to train in 
his laboratory. Thank you for your patience and kind heart. I have learned so many things from 
you. 
 
I am incredibly thankful for my dissertation committee: Drs. Charles Cobb, Danny Winder, 
Aurelio Galli, Kristina Hill, and Roger Colbran. They have really encouraged me when the 
journey became difficult and have challenged me to do my best.  
 
I would like to thank past mentors of the May Laboratory, Drs. Lying Li and Fiona Harrison. 
Thank you for your guidance and support. I am also thankful for past members in the lab that 
have contributed to the progress of my project, Drs. Zhichao Qu, Huan Qiao, Xiumei Chi, 
Richard Whitesell, Seth Weaver and Semiha Dede. A special thanks to Elizabeth Meredith, the 
best bay-mate one could ask for. I had the privilege to work with several undergraduates during 
my time in the May laboratory: Danielle DiAsio, Laurisa Rodrigues, Amita Raj and L. Nora 
Zeidan. Thank you for your hard work and enthusiasm. Also thanks to William Parker, for being 
my late-night-at-the-lab working buddy. 
 
I am incredibly thankful to Dr. Masakazu Shiota for always lending an encouraging ear 
throughout my studies. I appreciate that your door is always and your support has been 
invaluable. Other scientists that have been priceless are Drs. Maureen Hahn and Jana Shirley-
Rice, Beth Ann McLaughlin, and Jeannette Stankowski along with Rebecca Klar and Katherine 
iv 
Betke.  They have provided me with the technical support and skills to tackle the synaptosome 
studies. Special thanks to the members of the Galli Lab who allowed me to participate at lab 
meetings and especially, Drs. Heiner Matthies and Kevin Erreger for their scientific expertise in 
transporter studies.  
 
Dr. Alyssa Hasty has been a great Director of Graduate Studies and has always made sure that 
the students obtain the support they need from the program. Thank you Angie Pernell, who 
helped with so many aspects of planning and for always listening. I would like to especially 
acknowledge the BRET office, especially Drs. Kim Petrie and Roger Chalkley for providing so 
many wonderful opportunities to obtain great career advice. 
 
There are countless Nashville friends and families who helped me along this journey with their 
encouraging words, needed distractions and uplifting gifts. Words cannot express my sincerest 
gratitude.  
 
I would also like to thank my undergraduate mentor, Dr. Richard Gregory and the Ronald E. 
McNair coordinators, Dr. Kathryn Wilson and Vicki Bonds for all of your professional support 
and encouragement. You have contributed so much to my training as a scientist. 
 
Last, but not least, funding for this research has been provided by the Molecular Endocrinology 
Training Grant, 5T32DK07563 (PI: Richard O’Brien), 5 T32 AR59039 (PI: Thomas Ward) and 
National Institutes of Health grant NS 057674 (PI: James May). 
  
v 
TABLE OF CONTENTS 
 
Page 
 
DEDICATION ............................................................................................................................... ii	  
ACKNOWLEDGEMENTS ........................................................................................................... iii	  
LIST OF FIGURES .................................................................................................................... viii	  
LIST OF TABLES ......................................................................................................................... x	  
TABLE OF ABBREVIATIONS .................................................................................................... xi 
 
CHAPTER  
 
 I.    INTRODUCTION ................................................................................................................... 1 
 
OVERVIEW OF VITAMIN C IN HEALTH .............................................................................. 1	  
History of Vitamin C ........................................................................................................... 1	  
Chemistry of Vitamin C ...................................................................................................... 2	  
Vitamin C Functions ........................................................................................................... 4	  
Antioxidant functions ...................................................................................................... 4	  
Recycling: Vitamins C and E function as co-antioxidants in lipid peroxidation ............... 4	  
Vitamin C and Tetrahydrobiopterin Recycling ................................................................ 5	  
Vitamin C serves as a co-factor for monoxygenases and dioxygenases. ...................... 6	  
Adequate amounts of vitamin C ..................................................................................... 9	  
State of Vitamin C status in the US and effects on health ............................................... 10	  
Importance of Vitamin C in the brain ................................................................................ 11	  
VITAMIN C TRANSPORT REGULATION ........................................................................... 12	  
Regulation of Brain Vitamin C Uptake ............................................................................. 12	  
Glucose Transporters ................................................................................................... 12	  
Sodium Dependent Vitamin C Transporters ................................................................. 13	  
SVCT2 Background ...................................................................................................... 14	  
Regulation of Vitamin C Efflux in Brain ............................................................................ 17	  
Volume-Regulated Anion Channels ............................................................................. 18	  
Ascorbate-ascorbate homeoexchange ......................................................................... 19	  
Glutamate-ascorbate heteroexchange ......................................................................... 19	  
Investigating vitamin C regulation and its effects on behavior ......................................... 20	  
SPECIFIC AIMS .................................................................................................................. 21	  
 
II.    MATERIALS AND METHODS ............................................................................................ 22	  
 
ANIMAL MODELS ............................................................................................................... 22	  
vi 
Wild type (Gulo+/+; SVCT2 +/+) .......................................................................................... 22	  
L-gulonolactone oxidase deficient mice (Gulo-/-) .............................................................. 22	  
Sodium-dependent Vitamin C Transport Type 2 heterozygous mice (SVCT2+/-) ............. 22	  
L-gulonolactone oxidase and SVCT2 deficient mice (Gulo-/-; SVCT2+/-) .......................... 23	  
EXPERIMENTAL DIETS ..................................................................................................... 24	  
BEHAVIORAL ASSESSMENTS .......................................................................................... 25	  
Weight .............................................................................................................................. 25	  
Motor & Strength Assessments ....................................................................................... 25	  
Gait Analysis ................................................................................................................ 25	  
Locomotor Activity ........................................................................................................ 25	  
Inverted Screen ............................................................................................................ 25	  
Rota-rod Activity ........................................................................................................... 26	  
Wire Hang .................................................................................................................... 26	  
Horizontal Beam ........................................................................................................... 26	  
Zero Maze .................................................................................................................... 26	  
Y-Maze ......................................................................................................................... 27	  
SYNAPTOSOME PREPARATIONS AND FUNCTIONAL ASSESSMENTS ....................... 28	  
Crude Synaptosome Preparation ..................................................................................... 28	  
Enriched Synaptosome Preparation ................................................................................ 29	  
Synaptosome Fractionation ............................................................................................. 30	  
Concentration of cytosolic/perisynaptic and presynaptic fractions ................................... 31	  
Fura Red-AM Assay ......................................................................................................... 31	  
BIOCHEMICAL ASSESSMENTS ........................................................................................ 32	  
Tissue Preparations and Assays ..................................................................................... 32	  
Protein determination ................................................................................................... 32	  
Western blot analysis ................................................................................................... 33	  
Genotyping ................................................................................................................... 34	  
Antioxidant Analysis ......................................................................................................... 35	  
Vitamin C ...................................................................................................................... 35	  
Vitamin E ...................................................................................................................... 35	  
Reduced glutathione .................................................................................................... 35	  
Oxidative Stress Analysis ................................................................................................ 35	  
F4-neuroprostanes and F2-isoprostanes ....................................................................... 35	  
       STATISTICAL ANALYSIS ................................................................................................... 36 
Behavioral Data .............................................................................................................. 36 
Biochemical and oxidative stress markers ...................................................................... 36	  
 
III.   COMBINED VITAMIN C AND E DEFICIENCY INDUCES MOTOR DEFECTS IN  
       GULO−/−/SVCT2+/− ............................................................................................................... 38	  
 
INTRODUCTION ................................................................................................................. 38	  
PILOT STUDY ..................................................................................................................... 40	  
EXPERIMENTAL DESIGN AND BEHAVIOR ASSESSMENT SCHEDULE ........................ 43	  
Experiment 1 Design ........................................................................................................ 43	  
Experiment 1 Behavior Assesment Schedule .................................................................. 45	  
Experiment 2 Design ........................................................................................................ 45	  
Experiment 2 Behavior Assesment Schedule .................................................................. 47	  
RESULTS ............................................................................................................................ 47	  
Experiment 1 - Combined vitamin C & E deficiency in Gulo-/- mice ................................. 47	  
Body Weight and general appearance ......................................................................... 47	  
vii 
Behavioral Assessment ................................................................................................ 47	  
VC and α-Tocopherol measurements of brain cortex, and liver ................................... 50	  
Measures of oxidative stress ........................................................................................ 51	  
Experiment 2 - Combined vitamin C & E deficiency in gulo-/-/SVCT2+/- mice ................... 54	  
Body Weight and general appearance ......................................................................... 54	  
Behavioral Assessment ................................................................................................ 54	  
Vitamin C & E content of brain cortex, cerebellum and liver ........................................ 58	  
Measures of oxidative stress ........................................................................................ 59	  
DISCUSSION ...................................................................................................................... 62	  
 
IV.   VITAMIN C TRANSPORT AT THE NERVE TERMINAL .................................................... 67	  
 
INTRODUCTION ................................................................................................................. 67	  
RESULTS ............................................................................................................................ 70	  
Neuronal SVCT2 localization ........................................................................................... 70	  
SVCT2 expression at the cortical pre-synaptic terminal .................................................. 72	  
SVCT2 function in crude cortical synaptosomes ............................................................. 74	  
Net VC uptake .............................................................................................................. 74	  
Kinetic characterization of VC uptake .......................................................................... 76	  
Net VC efflux out of cortical synaptosomes ..................................................................... 76	  
Temperature dependence of spontaneous VC efflux ................................................... 76	  
Hypotonic-Induced VC Efflux ....................................................................................... 79	  
Glutamate-Induced VC Efflux ....................................................................................... 80	  
DISCUSSION ...................................................................................................................... 82	  
 
V.   SUMMARY AND CONCLUSIONS ...................................................................................... 87	  
       
      BACKGROUND .................................................................................................................... 87	  
      COMBINED VITAMIN C AND E DEFICIENCY ALONG WITH DECREASED SVCT2  
      EXPRESSION CAUSES MOTOR COORDINATION DEFECTS ......................................... 88	  
Possible causes of neurobehavioral changes in cellular vitamin C deficiency. ............... 90	  
Acute generalized (whole body) scurvy ........................................................................ 90	  
Imbalance in energy homeostasis ................................................................................ 90	  
Dysregulation of vitamin C uptake via altered neuronal SVCT2 expression impairs 
neuronal function. ......................................................................................................... 91	  
       TRANSPORT OF VITAMIN C IS TIGHTLY REGULATED AT THE NERVE  
       TERMINAL IN THE CNS ..................................................................................................... 92	  
What implications does this research have for in vivo models? ....................................... 95	  
 
APPENDIX ................................................................................................................................. 97	  
 
PILOT STUDY BIOCHEMICAL AND BEHAVIOR ASSESMENT ........................................ 97	  
 
REFERENCES ......................................................................................................................... 100	  
 
  
viii 
LIST OF FIGURES 
 
 
Figure                                                                                                                                     Page 
	  
1.1    VC Metabolism ................................................................................................................... 3	  
 
 
1.2    Visualization of In situ hybridization staining for SVCT2 gene expression in  
          
         mouse brain. .................................................................................................................... 15 
 
 
1.3    Structural model of SVCT2 . ........................................................................................... 17	  
 
 
2.1    Flowchart of Overall Synaptosome Preparation ........................................................... 28	  
 
 
2.2    Flowchart of Synaptosome Fractionation ..................................................................... 31	  
 
 
3.1    Experimental Scheme 1, Combined vitamin C & E deficient diets ............................. 44	  	  
 
 
3.2    Experimental Scheme 2, Combined vitamin deficiency effects on gulo-/- SVCT2 +/-  
          
         mice. .................................................................................................................................. 46	  
 
 
3.3    Behavioral phenotype of combined vitamin C & E deficiency .................................... 49	  
 
 
3.4    Combined vitamin C & E deficiency decreases antioxidant levels in cortex and  
 
         liver ................................................................................................................................... 52	  
 
 
3.5    Vitamin E deficiency induces oxidative stress ............................................................. 53	  
 
 
3.6    Genetic modification of gulo-/-/SVCT2+/- alters behavioral phenotype ........................ 57	  
 
 
3.7    Combined vitamin C & E deficiency decreases antioxidants in cortex, cerebellum   
          
         and liver in gulo-/-/SVCT2+/- .............................................................................................. 60	  
 
 
ix 
3.8    Combined vitamin C & E deficiency increases oxidative stress in cortex and  
 
         liver in gulo-/-/SVCT2+/- ..................................................................................................... 61 
 
 
4.1    Immunostaining of the SCG presynaptic bouton ......................................................... 73	  
 
 
4.2    SVCT2 is localized in pre-synaptic fractions ................................................................ 73	  
 
 
4.3    Net Vitamin C uptake in cortical crude synaptosomes ................................................ 75	  
 
 
4.4    Synaptosome membrane integrity is maintained during the course of experiment. 77 
 
 
4.5    Spontatneous Vitamin C Efflux. ..................................................................................... 78 
 
 
4.6    Hypotonic solution-induced vitamin C efflux ............................................................... 79	  
 
 
4.7    Glutamate concentration curve. ..................................................................................... 80	  
 
 
4.8    Glutamate Induced Vitamin C Efflux .............................................................................. 81	  
 
 
4.9    Model of Vitamin C Uptake and Efflux at a Representative Nerve Terminal .............. 86	  
 
  
x 
LIST OF TABLES 
 
 
Table                                                                                                                                       Page 
 
1.1    Enzymes that require Tetrahydrobiopterin function ...................................................... 6	  
 
 
1.2    Monoxygenases that require Vitamin C as a co-factor .................................................. 7	  
 
 
1.3    Dioxygenases that require Vitamin C as a co-factor ...................................................... 8	  
 
 
1.4    Correlation between scurvy symptoms and loss in the activity of specific  
 
         dioxygenases due to vitamin C deficiency. .................................................................... 9	  
 
 
1.5    Recommended Dietary Allowances (RDAs) for Vitamin C .......................................... 10	  
 
 
2.1    Macronutrient compositions of experimental diets utilized in Specific Aims I-II ...... 24	  
 
 
3.1    Pilot Study - Summary of the effects of combined Vitamin C and E deficiency on  
 
         experimental mice groups. . ........................................................................................... 42	  
 
 
3.2    Summary of the effects of combined Vitamin C and E deficiency on experimental  
 
         mice groups. .................................................................................................................... 42	  
  
  
xi 
LIST OF ABBREVIATIONS 
 
AMP adenosine monophosphate 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AMPK 5' adenosine monophosphate-activated protein kinase 
BCA bicinchoninic acid  
BH4 tetrahydrobiopterin 
BSA bovine serum albumin  
CNS central nervous system 
CSF cerebral spinal fluid 
DDF dideoxforskolin 
DHA dehydroascorbic acid  
DHPG (S)-3,5-dihydroxyphenylglycine 
DIDS 4,4′- diisothiocyanatostilbene-2,2′-disulfonic acid 
DMSO dimethyl sulfoxide 
DOPA 3,4-hydroxyphenyl alanine  
EAAC1 excitatory amino-acid carrier 1 
GABA γ-aminobutyric acid 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GLAST glutamate aspartate transporter 
GLT-1 glutamate transporter-1 
GLU glutamate 
GLUT glucose transporter 
GPβ G-protein β subunit 
GSH reduced glutathione  
Gulo gulonolactone oxidase enzyme 
HEK human embryonic kidney 293 cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC high-performance liquid chromatography 
iGluR inotropic glutamate receptors 
KRH Krebs-ringer HEPES buffer 
MDA malondialdehyde  
mGluR metabotropic glutamate receptor 
NADPH nicotinamide adenine dinucleotide phosphate-oxidase 
NET norepinephrine Transporter 
NMDAR-1 N-methyl-D-aspartate Receptor 
NPPB 5-nitro-2-(3-phenylpropylamino) benzoic acid 
PLN phloretin 
PSD-95 postsynaptic density protein 95  
RDA recommended dietary allowance 
RNS reactive nitrogen species 
ROS reactive oxygen species 
SCG superior cervical ganglion 
xii 
SDS sodium dodecyl sulfate 
SEM standard error of the mean 
SITS 4-aceta- mido-4′-isothiocyanostilbene-2,2′-disulfonic acid  
SLC23A solute carrier family 23 member 1, SVCT2 
SPZ sulfinpyrazone 
SVCT2 sodium - dependent vitamin C transporter type-2 
TCA trichloroacetic acid 
TH tyrosine hydroxylase  
VC vitamin C 
VE vitamin E 
VMAT2 vesicular monoamine transporter–type 2,  
VRAC volume-regulated anion channel 
VSOAC volume-sensitive osmolyte and anion channel  
 
 CHAPTER I 
 
INTRODUCTION 
 
OVERVIEW OF VITAMIN C IN HEALTH 
History of Vitamin C 
As with most medical breakthrough discoveries, the beginning of vitamin C (VC) research was 
initiated by necessity and urgency. VC is an essential micronutrient for humans as its deficiency 
leads to scurvy, a life-threating condition characterized by fatigue, hemorrhages, bleeding gums, 
and eventually death. Early accounts of the disease may date as far back as the ancient 
Egyptians (1-3). Since then, the cure for scurvy seems to have been discovered, forgotten and 
rediscovered numerous times (4). For decades, sailors suffered from the disease after long 
voyages at sea. In 1753, James Lind, a Scottish physician aboard the H.M.S. Salisbury, 
performed the first recorded clinical trial that investigated whether dietary intervention could 
offer his disease-stricken crewmates some reprieve (5). At the time, it was postulated that acid 
or malt wort contained the cure (5). He assessed the effects of six different remedies in two 
seaman each that spanned six days: [1] a quart of cider, [2] twenty-five drops of elixir vitriol 
(mixture of sulfuric acid, alcohol, and aromatics - usually ginger and cinnamon), [3] two 
spoonful’s of vinegar, [4] a course of sea-water, [5] two oranges and a lemon, and [6] a nutmeg, 
garlic, and mustard seed concoction. He documented that citrus fruits, particularly lemons and 
oranges, were the only food that relieved the sailors’ symptoms and afforded them full recovery. 
He concluded that an “anti-scorbutic factor” in these food items was the key to preventing 
scurvy (6). After decades of the British Navy disregarding Lind’s findings, lemon or lime juices 
were finally incorporated into sailors’ rations in the mid-1800’s.  
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It was not until the first half of the 20th century when various conditions began to be described 
as diseases due to deficiency of an essential nutrient. In 1912, Casmir Funk proposed a list of 
“vitamins”; compounds not synthesized within the body whose deficiency lead to severe 
diseases. In this list he used the letter “C” to denote the still unidentified factor known to cure 
scurvy (7). In 1929, the factor was isolated and identified. A research team led by the Hungarian 
chemist Albert Szent-Gyorgyi described the molecule’s ability to inhibit biological oxidation 
reactions (8). It was originally called L-hexuronic acid, but when it was found to have anti-scurvy 
activity in animals, the suggestion was made to rename the compound to ascorbic acid, derived 
from a- (meaning "no") and scorbutus (scurvy). Szent-Gyorgyi later shared the Nobel Prize for 
his discovery of the structure of ascorbic acid.  
 
Both animals and plants need ascorbic acid to live. All plants and most mammals can 
synthesize ascorbic acid from glucose in liver. In 1957, Albert Lehninger determined that unlike 
most species, humans are not able to perform the crucial last step in the synthesis pathway: 
conversion of l-gulono-γ-lactone into ascorbic acid via the gulonolactone oxidase enzyme. 
Nishikimi & Yagi (9) discovered that the gene responsible for coding the enzyme is present but 
non-functional due to several mutations. In fact, gorillas, chimps, orangutans, some monkeys, 
guinea pigs and select bats have this phenotype. Therefore, ascorbic acid is only a true 
“vitamin” to a select few species and must simply be considered an essential nutrient in others.  
Chemistry of Vitamin C 
Ascorbic acid, the reduced form of VC, is the species that contains all known biological activity. 
It is water-soluble and at neutral pH it is ionized at the C-3 hydroxyl group (Figure 1.1) (4). At 
the heart of its versatility is the capacity to donate up to two electrons to other compounds. The 
one-electron oxidation of ascorbic acid results in the relatively inactive ascorbate free radical 
3 
being formed.  NADH- and NADPH-dependent reductases within the cell are able to reduce this 
radical back to ascorbic acid. However, when the radical accumulates, two of these molecules 
can dismutate, resulting in one molecule of ascorbic acid and one molecule of dehydroascorbic 
acid (DHA). Due to the structural stress on the molecule caused by three ketone groups, the 
half-life of DHA is very short in physiologic buffers (~6 mins) (10;11). The cell can readily reduce 
DHA back to ascorbic acid by glutathione (GSH), thiol transferases or NADPH-dependent 
reductases (12).  The name ‘vitamin C’ refers to the combination of all three molecules (ascorbic 
acid, ascorbate free radical and dehydroascorbic acid) in biological systems since all of the 
oxidized states of ascorbic acid are eventually reduced to active form. Over 98% of VC in 
plasma exists as ascorbic acid, with dehydroascorbate concentrations on the order of 1-2 µM 
(13).  Therefore, for simplicity I will refer to ascorbate and ascorbic acid as VC whenever the 
distinction between the two is irrelevant. 
 
 
 
Figure 1.1: VC Metabolism. Adapted from (4) 
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Vitamin C Functions 
Antioxidant functions 
 Oxidative stress arises from the imbalance of oxidants and antioxidants in favor of the former. 
Accumulation of these molecules can lead to damage to lipids, proteins or DNA and can 
eventually cause cellular death. VC is one of the most important low molecular weight 
antioxidants. Chain-breaking donor antioxidants, like VC, provide an electron, often with an 
accompanying proton, to reduce radical species (Figure 1.1). This slows or eliminates 
potentially damaging oxidative chain reactions after they begin. VC also acts as a direct 
antioxidant to scavenge end-phase oxidants, such as peroxynitrite, which would otherwise 
damage cellular proteins. It reacts both with endogenous (14) and exogenous reactive oxygen 
species (ROS) and to a certain extent, reactive nitrogen species (15-17). 
Recycling: Vitamins C and E function as co-antioxidants in lipid peroxidation 
A synergistic relationship exists between water-soluble VC and lipid-soluble vitamin E (VE), 
particularly α-tocopherol. While the vitamins partition to different parts of the cell, the phenol 
group of tocopherol, the site of antioxidant action, is at the water-membrane interface and easily 
accessible to VC (18). VC donates an electron to the α-tocopheroxyl radical and thus restores 
its ability to intercept carbon- or oxygen-based radicals in the lipid phase. The physiologic 
implications have been demonstrated in numerous in vitro and in vivo studies in which VC has 
been shown to preserve or at least spare α-tocopherol in lipid micelles, cell membranes, and in 
human erythrocytes. It has been more difficult to show sparing in vivo, but two more recent 
studies have strongly suggested this synergism between the two vitamins. 
 
In guinea pigs, which cannot make either vitamin, Hill, et al. (19) found that after 3 weeks of a 
VE-deficient diet, as little as 5 days of VC deprivation led to an ascending paralysis and a 
5 
respiratory death in most animals. This phenotype may reflect the neuronal damage associated 
with VE deficiency, not scurvy. No changes were observed in guinea pigs deficient in only a 
single vitamin. Surprisingly, although F2-isoprostanes in liver and brain were increased in the 
doubly deficient animals, this increase was modest. Nonetheless, subsequent studies (20) 
confirmed the neurologic damage due to inflammation by showing widespread destruction of the 
long-track neurons in the pons and spinal cord in the doubly deficient animals, but no sign of 
damage in either single deficiency. Indeed, VC prevents loss of α-tocopherol and decreases 
lipid peroxidation in cultured neuron cells subjected to oxygenated medium (21). Together, 
these studies suggested that a modest decrease in CNS VC significantly accelerated VE 
deficiency syndrome. 
 
More recently, evidence for a sparing effect of VC on α-tocopherol has been found in human 
smokers (22). In this study, smokers were found to have decreased plasma α- and γ-tocopherol 
levels that were completely restored to normal after 3 days of supplementation with 500 mg of 
VC daily. These results could reflect scavenging of smoke-derived radicals to spare α-
tocopherol, but also support the notion derived from in vitro and animal studies that VC recycles 
VE. 
Vitamin C and Tetrahydrobiopterin Recycling  
VC also recycles an important enzyme cofactor, tetrahydrobiopterin (BH4), thus keeping it in its 
reduced state to allow for full catalytic activity (23;24). BH4 reduces Fe3+ back to Fe2+ to maintain 
activation and by so doing preserves the catalytic iron of several dioxygenase enzymes in the 
active ferrous form (25). Table 1.1 lists known enzymes that require BH4 to function properly. 
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Vitamin C serves as a co-factor for monoxygenases and dioxygenases. 
Oxygenases incorporate one or two atoms of dioxygen in a variety of substrates in metabolic 
pathways. Monooxygenases are enzymes that incorporate one hydroxyl group as two atoms of 
dioxygen are reduced to one hydroxyl group and one H2O molecule by the concomitant 
oxidation of NADPH. Dioxygenases are enzymes that incorporate two dioxygen atoms into 
substrates (26). Oxygenases are involved in many pathways including catecholamine, 
neuropeptide, and collagen synthesis. VC serves as a co-factor for both monooxygenases 
(Table 1.3) and dioxygenases (Table 1.3). Indeed, scurvy is a disease caused by the 
malfunction of several key dioxygenases. (Table 1.4). 
 
 
Table 1.1: Enzymes that require Tetrahydrobiopterin function. 
 
Enzyme Function 
Tyrosine hydroxylase (TH) Responsible of the conversion of tyrosine to 3,4-
hydroxyphenyl alanine (DOPA), the first and rate-limiting 
step of norepinephrine synthesis 
 
Phenylalanine hydroxylase Catalyzes L-tyrosine from L-phenylalanine. Its deficiency 
causes phenylketonuria.  
 
Tryptophan hydroxylase First and rate-limiting step in serotonin synthesis, 
catalyzing the production of 5-hydroxy-tryptophan from L-
tryptophan 
 
Alklglycerol monooxygenase Catalyzes the formation of 1-hydroxyalkyl-sn-glycerol 
from 1-alkyl-sn-glycerol 
 
Nitric oxide synthase Catalyzes production of L-citrulline and nitric oxide from 
L-arginine and is key for nitric oxide generation   
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Table 1.2: Monoxygenases that require Vitamin C as a co-factor. 
 
Enzyme  Function Reference  
Dopamine-β-hydroxylase Catalyzes the conversion of dopamine to 
norepinephrine. It is soluble within vesicles and 
also exists as a constituent of the membranes of 
secretory vesicles of norepinephrine-producing 
neurons in the CNS, sympathetic ganglia and 
adrenal medulla cells. It requires copper as a 
cofactor and oxygen and VC as co-substrates. 
 
(27;28) 
(29) 
Peptidylglycine α-amidating 
monoxygenase 
Catalyzes the production of α-amidated peptides 
from neuroendocrine peptides and is crucial for 
neurotransmitter synthesis as well 
 
(30) 
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Table 1.3: Dioxygenases that require Vitamin C as a co-factor. 
 
Enzyme Function Reference  
6-N-trimethyl-L-lysine 
hydroxylase and γ- 
butyrobetaine hydroxylase 
Two VC dependent dioxygenases that are 
required in carnitine synthesis. 
(31) 
 
Aspartyl (asparaginyl) β-
hydroxylase 
 
Responsible for the post-translational 
modification of Asp residues present in EGF-like 
domains. 
 
 
(32) 
4-hydroxyphenylpyruvate 
dioxygenase 
An Fe(II) containing non-heme oxygenase, which 
catalyzes the oxidation of 4-
hydroxyphenylpyruvate to homogentisate. This is 
one of the many steps in tyrosine catabolism and 
oxidation.  
 
(33) 
Proyl and lysyl hydroxylases Catalyzes hydroxylation of proline or lysine to 
hydroxyproline and hydroxylysine, respectively. 
These selective modifications are essential for 
proper collagen folding. 
Lack of VC leads to the formation of 
dysfunctional collagen in blood vessels and 
bones. Furthermore, a novel class of prolyl 
hydoxylases has been shown to regulate gene 
expression via the transcription factor HIF1α. VC 
supplies electrons reguired for the hydroxylation 
of HIF1α, which then targets the transcription 
factor for proteosomal degradation, thus 
decreasing its activity.  
 
(7;34) 
(7;35) 
(36;37) 
Jumonji histone demethylase 
1a/1b (Jhdm1a/1b) 
Catalyzes the formation of mono-methylated 
histone H3 form α-ketoglutarate and trimethyated 
histone H3. This may account for the recent 
findings that VC is required for progression of 
stem cells through differentiation and 
development.  
 
(38-40) 
 
Nucleic acid demethylase Catalyzes the production of thymine in DNA from 
α-ketoglutarate and 3-methyl- thymine found in 
DNA. This also may contribute to epigenetic 
regulation by VC.  
(39) 
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Table 1.4: Correlation between scurvy symptoms and loss in the activity of specific 
dioxygenases due to vitamin C deficiency. Adapted from (31) 
 
Symptom Putative Target affected Dioxygenase(s) Involved 
Hemorrhages/ Spots Blood vessels  
Various collagen types (III,IV) 
 
Prolyl/lysyl hydroxylase 
Rotten or loose teeth Dentin  
Various collagen types (I, II, IV) 
 
Prolyl/lysyl hydroxylase 
Rigid tendons Various collagen types (I, XII, XIV) 
 
Prolyl/lysyl hydroxylase 
Bone/ Cartilage fragility Various collagen types (I, II, IX, X, XI) Prolyl/lysyl hydroxylase 
 
Lassitude 
 
Carnitine biosynthesis 
 
Trimethyl-lysine 
dioxygenase butyrobetaine 
dioxygenase 
Vision problems Synthesis of vitamin A β-carotene 15-15’ 
dioxygenase 
 
Neurological disorders Noradrenaline/ dopamine 
biosynthesis 
Tyrosine hydroxylase 
dopamine hydroxylase 
 
 
Adequate amounts of vitamin C 
Due to the critical roles played by VC, obtaining and sustaining adequate cellular concentrations 
is essential. In humans, a physiologic deficiency of VC will occur in about 90 days when normal 
body stores, usually ~1500 mg, decrease below 350 mg or serum levels reach <11.4 µM (2).  
 
As little as 10 mg/day of VC is needed to maintain stores > 11.4 µM and prevent scurvy, 
however saturation of plasma and tissue levels occurs at 200 mg/day (70 µM) (41). Excess 
amounts will be excreted as unmetabolized VC in the urine (42). Fruits and vegetables are the 
best sources of VC. Citrus fruits, tomatoes and tomato juice, and potatoes are major 
contributors of VC to the American diet (43). Currently in the U.S., the Recommended Dietary 
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Allowance (RDA) for VC is 120% of the estimated average requirement and therefore is 90 
mg/day for adult men and 75 mg/day for adult women. This concentration was set based on 
levels needed to maintain near-maximal neutrophil concentration with minimal urinary excretion 
of VC (42). There is growing evidence that the amount needed for optimal health is far more 
than that. In scenarios where there is an increase of oxidative stress and the subsequent 
metabolic turnover of VC, such as smoking, lactation, pregnancy, the requirement is increased 
by 35 mg/day (43). 
 
 
Table 1.5: Recommended Dietary Allowances (RDAs) for Vitamin C. Taken from (41) 
 
Age Male Female Pregnancy Lactation 
0–6 months 40 mg* 40 mg*    
7–12 months 50 mg* 50 mg*    
1–3 years 15 mg 15 mg    
4–8 years 25 mg 25 mg    
9–13 years 45 mg 45 mg    
14–18 years 75 mg 65 mg 80 mg 115 mg 
19+ years 90 mg 75 mg 85 mg 120 mg 
 
Smokers 
 
Individuals who smoke require 35 mg/day more VC than nonsmokers. 
* Adequate Intake (AI) 
 
 
State of Vitamin C status in the US and effects on health 
In the 2012 National Report of Biochemical Indicators of Diet and Nutrition in U.S Population, 
(http://www.cdc.gov/nutritionreport/pdf/Nutrition) serum VC concentrations were reported to be 
deficient (< 11.4 µM) in 6% of the population 6 years and older. This is estimated to be 15.8 
million people. At least the same amount of people had low (11.4 - 23 µM) VC levels. Although 
overt scurvy manifestation is rare, it is likely that this population may develop a form of latent 
scurvy characterized by fatigue, dull aches and irritability (2;44).  Furthermore, since scurvy is 
relativity uncommon in the US, occasionally it is misdiagnosed based on symptoms. Low levels 
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of VC can lead to loss of bone mass, inadequate collagen formation, hemorrhaging, decline in 
cellular energy status, impaired neurotransmitter production and eventually death (45). This is 
especially relevant for individuals with low intake due to psychiatric disorders or alcoholism that 
present to clinicians with rheumatologic or dermatologic complaints that mask the underlying 
signs of early scurvy (45-47). Therefore, awareness of the disease is essential to make the 
proper diagnosis. 
Importance of Vitamin C in the brain 
The brain is perhaps one of the most sheltered organs during progression of VC deficiency, 
having both some of the highest levels of VC in any organ, achieved by a unique two-step 
concentrative mechanism (discussed below). For example, whereas cells within most organs 
have VC levels of 1-2 mM, those within brain can be as high as 4-6 mM (48). Further, neurons 
have rates of oxidative metabolism as high at ten-fold those of other tissues (49) and thus are 
likely to generate more ROS than other cell types. The burden of oxidative stress warrants the 
high antioxidant VC levels in neural tissues. This may be especially important in 
neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s, in which there 
is oxidative stress due to secondary inflammation (50;51). Another factor in both health and 
disease is likely the role of VC as co-factor for several crucial dioxygenase enzymes in the CNS, 
as described above. Finally VC has been implicated in neurotransmitter regulation (52), as will 
be discussed below. 
 
However, there is a huge gap in the understanding the role of VC in brain health and disease 
due to the lack of information on the mechanisms involved in tissue distribution and 
homeostasis. It is this lack that prompted the selection of this thesis project, first to determine 
whether vitamins C and E interact to support behavior in vivo, then to dissect potential 
mechanisms at the sub-cellular level by studying VC uptake, efflux, and metabolism in the 
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neuronal synapse. Key to both of these topics is what is known of brain and VC homeostasis. 
Although most information relates to VC uptake by the brain and CNS, our work also suggests a 
role for efflux in of the vitamin, at least in synapses. Accordingly the next sections will discuss 
VC transport regulation, with emphasis on the brain and neurons. 
 
VITAMIN C TRANSPORT REGULATION  
 
Plasma VC levels depend on dietary absorbance and/or hepatic synthesis and ultimately 
determine the concentration available for all tissues (41;42). Therefore all species depend on 
transport of VC across cell membranes for redistribution into other tissues. VC transport 
between tissues is a balance of uptake and efflux. While VC uptake mechanisms are well 
established, identification of the proteins mediating efflux still remains elusive. The brain, as 
noted above, is unique among organs in having a two-step uptake mechanism that derives from 
its transporter, the Sodium-dependent VC Transporter type 2 (SVCT2) (53). Although the 
SVCT2 is likely to be the primary mechanism by which the brain acquires VC, there is another 
mechanism, as described next.  
Regulation of Brain Vitamin C Uptake 
Glucose Transporters 
DHA represents less than 5% of total VC in plasma and can be transported across the 
membrane via glucose transporters (54). A number of GLUTs: GLUT1, GLUT3, and GLUT4 
(55;56) recognize DHA because of structural similarity to glucose. However, these proteins do 
not recognize ascorbic acid. Facilitative transport of DHA is similar to glucose in that it is 
transported down a concentration gradient into cells. The affinity of glucose transporters for 
DHA is similar to that for glucose (57;58), thus, there is competition between the two substrates. 
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At normal physiologic glucose concentrations (5 mM), DHA uptake is likely very low, considering 
that its extracellular concentrations are very low micromolar, as noted previously. Although DHA 
can be transported across the blood-brain barrier when concentrations are high (59), 
competition with glucose deters this from being is not a major mechanism for VC entry into the 
brain (53). However, once DHA is in the cells, reduction mechanisms convert DHA to ascorbic 
acid very efficiently (17;60) and this mechanism could become important in cases of severe 
oxidative stress, such as in the periumbral area of stroke, where there is reperfusion after 
ischemia. Nonetheless, most brain VC under normal circumstances is acquired on the SVCT2, 
as described next. 
Sodium Dependent Vitamin C Transporters 
Ascorbic acid represents ~95% of total VC in plasma and is transported into tissues solely by 
SVCT’s. The Hediger group cloned two SVCT type transporters (61) from the solute carrier (Slc) 
transporter family. The Slc23a1 gene encodes the SVCT1 protein, and Slc23a2 encodes the 
SVCT2 protein. The two transporters share 65% amino acid identity with minor differences 
between species (61). They both have 12 trans-membrane spanning motifs with the N- and C- 
termini located on the cytoplasmic side of the membrane and several putative sites for post-
translational modification. These transporters are stereospecific for L-ascorbic acid and are 
driven by the Na+ electrochemical gradient. In a two- step manner, SVCT1 and SVCT2 work in 
concert to maintain proper levels of VC within the body. These isoforms have different tissue 
distribution, and functional properties depending on the cell, tissue and species.  
 
SVCT1 (slc23A1) mRNA is found in epithelial tissues involved in VC absorption (intestine) and 
re-absorption (kidney).  SVCT1 has a low affinity for VC (apparent Km 66-237 µM) and higher 
capacity (Vmax) compared to SVCT2 (62). SVCT1-deficient mice have VC levels about half 
normal, but appear to develop normally and have sufficient VC tissue levels to prevent scurvy. 
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Once VC is in the plasma, SVCT2 helps distribute the vitamin to all of the other cell types. Two 
other SVCT orphan transporters (SVCT3 and SVCT4) have been cloned, but are most likely 
nucleobase transporters and are not known to transport VC (63). 
SVCT2 Background   
SVCT2 depends on Na+ ions as replacement with K+, Li+ or choline abolishes uptake (64). The 
transport cycle for SVCT2 is characterized by the transport of 2 molecules of Na+ for every one 
molecule of VC. Na+ increases the transport rate of VC in a cooperative manner by decreasing 
the transport Km without affecting the Vmax. Therefore, SVCT2 (in most cells) has a relatively 
high affinity for VC (Km = 20-40 µM), reflective of plasma concentrations (30-50 µM).  Godoy, et 
al. showed that Ca2+ and Mg2+ ions are also required for SVCT2 function (65).  
 
SVCT2 (slc23a2) mRNA and protein expression is evident in liver, lung, placenta, eye, and 
spleen. However, the highest expression is in brain in areas of high neuronal density like the 
hippocampus and cerebellum (66). The heterogeneous distribution of SVCT2 in the brain can 
be appreciated in the visualization of SVCT2 gene expression provided by the in situ 
hybridization staining depicted in the Allan Brain Atlas (Figure 1.2).  
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Figure 1.2: Visualization of In situ hybridization staining for SVCT2 gene expression in 
mouse brain. (Image credit: Allen Institute for Brain Science, mouse.brain-map.org) 
 
 
The mechanisms that regulate SVCT2 expression are yet to be defined. Mice that are 
homozygous knock-out mutants for SVCT2 die at birth with low levels of VC in organs that only 
express SVCT2 and undetectable levels in the brain (67), attesting to the importance of this 
transporter in brain health. VC is transported to the brain in a two-step mechanism because it 
cannot cross the blood-brain barrier. Indeed, the SVCT2 is not present in blood-brain barrier 
endothelial cells in vivo (68), perhaps accounting for failure of VC to enter the brain where the 
blood-brain barrier is very tight. In the first step, VC is transported from the blood to the CSF in 
the third ventricle by SVCT2 expressed in the epithelial cells that make up the choroid plexus. 
This generates CSF concentrations of 200-400 µM in humans (69;70). In the second step, VC is 
transported from the CSF into neurons via SVCT2 expressed in the neuronal plasma 
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membrane. This two-step mechanism contributes to neuronal VC concentration of ~3-10 mM, 
depending on neuronal density (71). Indeed, although neurons express the SVCT2 in 
abundance, glial cells do not express the protein in vivo, and thus likely have much lower VC 
contents (48). 
 
Currently, there are no biochemical or structural data for SVCT2 due to the fact that purified 
proteins have not been obtained. Primary amino acid sequence and Western blot analysis is the 
basis of all of the information available for SVCT2. Based on these analyses, SVCT2 has 
potential N-glycosylation sites on an exofacial loop between trans-membrane segments 3 and 4 
(61;72). Also, there are putative sites for protein kinase-A and protein kinase-C regulation on the 
cytoplasmic portions as shown in Figure 1.3 (61).  
 
There have been few studies correlating SVCT2 structure with function. Cell culture studies 
suggest that these sites are functional in acute regulation given that VC transport is decreased 
by both dibutyryl cyclic AMP (73;74) and by protein kinase-C agonists (72;75). Our lab has 
shown in endothelial and SH-SY5Y cells that transport rates are inhibited by extracellular 
sulfhydryl reagents, indicating the four exofacial cysteines may be involved in the transport 
mechanism (76). Our lab has also shown that SVCT2 is regulated by VC levels (77). There is 
also evidence that intracellular VC and GSH concentrations affect VC transport (76). Even 
under times of severe VC deficiency, the brain retains ~25% of original levels while the rest of 
the body has been depleted (78) suggesting that the brain may have efficient mechanisms for 
regulating VC transport. It is remains unclear if VC concentration can affect the transport of VC 
by altering SVCT2 affinity for VC. Despite the potential importance of the SVCT2 to brain VC 
levels, function, and antioxidant defense, as is evident from the foregoing, we know very little 
about how changes in the expression and function of the SVCT2 regulate VC homeostasis in 
the CNS.  
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Figure 1.3: Structural model of SVCT2 based on its hydropathy profile. Taken from (79)  
Schematic diagram based on the proposed sequence and hydropathy analysis of the human 
SVCT2 (64). The human SVCT2 is predicted to have 12 membrane-spanning regions with 
intracellular amino (NH2-) and carboxy (HOOC-) termini. Locations of potential extracellular 
glycosylation sites are noted in brown, cysteine residues are noted in green and sites for protein 
kinase C phosphorylation are noted in yellow.  
 
Regulation of Vitamin C Efflux in Brain 
The extracellular concentration of VC in the CSF has been shown to have significant impact on 
physiologic functions as discussed later in this chapter. Simple diffusion of VC out of cells 
across the plasma membrane is not thermodynamically probable due its size and negative 
charge. Furthermore, although DHA is more hydrophobic than VC and could exit on glucose 
transporters, DHA intracellular concentrations are low (12) and not likely to be the source of 
extracellular VC. As aforementioned, VC uptake is homeostatically regulated and there is 
increasing evidence that VC efflux mechanisms are regulated as well. Even though there has 
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been very little research devoted to elucidating these efflux mechanisms, a few possible 
pathways have arisen including: [1] volume-sensitive anion channels, [2] ascorbate-ascorbate 
homeoexchange, and [3] glutamate-ascorbate heteroexchange.  
Volume-Regulated Anion Channels 
A number of physiologic scenarios can cause cells to swell, during which the intracellular 
volume increases. Volume-Sensitive Osmolyte and Anion Channels (VSOACs) and Volume-
Regulated Anion Channels (VRACs) are anion channels located in the plasma membrane that 
mediate the compensatory decrease of intracellular volume and prevent the cell from bursting. 
While the molecular identities of the channels are uncertain (80), electrophysiological studies 
have shown that VC may be transported through these types of channels (81).  This type of VC 
efflux mechanism has been mostly studied in neurons and astrocytes and has received the 
most experimental support out of the three mechanisms mentioned (82;83). A variety cell types 
including hepatocyte-like HepG2 cells (84), coronary artery endothelial cells (85), K562 cells 
(86), astrocytes (87), and SH-SY5Y neuroblastoma cells (83) have shown VC efflux that is 
sensitive to anion channel blockers, suggesting that such channels facilitate this pathway. 
These studies use generic anion channel inhibitors such as 4,4′- diisothiocyanatostilbene-2,2′-
disulfonic acid (DIDS) and 4-aceta- mido-4′-isothiocyanostilbene-2,2′-disulfonic acid (SITS), and 
the VSOAC-inhibitors dideoxforskolin (DDF) and 5-nitro-2-(3-phenylpropylamino) benzoic acid 
(NPPB). More relevant to the likely function of these channels in cells, it has also been shown in 
astrocytes that hypotonic solutions can stimulate VC release in astrocytes by cell swelling (88).  
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Ascorbate-ascorbate homeoexchange  
The ascorbate-ascorbate homeoexchange theory is based on the observation that the addition 
of extracellular VC prompts the release of preloaded intracellular VC from adrenal cortical cells 
(89). Our lab has published a similar study using EA.hy926 endothelial cells, in which dose-
dependent release of preloaded 14C-VC was induced by the addition of unlabeled VC (90). A 
single transporter capable of this moving VC both in and out of cells has not been identified. An 
alternative explanation for this phenomenon is that SVCT2 is bidirectional, depending on local 
conditions.  While this activity is characteristic of facilitative diffusion transporters, such as the 
GLUTs, it is less likely to be a property of an energy and Na+-dependent transporter, such as 
the SVCT2. Further research is necessary to determine which, if any, physiologic conditions can 
allow this type of function.   
Glutamate-ascorbate heteroexchange  
The excitatory neurotransmitter L-glutamate activates glutamate receptors on the cell surface 
and synaptic cleft. Proper clearance of glutamate via uptake is essential as over-activation of 
these receptors causes oxidative stress and excitotoxicity. It has been shown that the uptake of 
extracellular glutamate stimulates VC efflux in astrocytes (52). Glutamate uptake is also 
associated with ischemia-induced efflux of VC from neurons and glia (71;91;92).  This data 
suggests that these two processes, glutamate uptake and VC efflux, may be linked in a single 
mechanism. The glutamate-ascorbate heteroexchange theory postulates that glutamate uptake 
is dependent on VC release and that there is a heteroexchange of the two molecules within the 
intracellular and extracellular space via one or more transporters (52;93;94). However, while 
Wilson and colleagues confirmed that glutamate increases VC efflux from cerebral astrocytes, 
intracellular VC did not have an effect on glutamate uptake, suggesting that heteroexchange 
may not be the correct mechanism (95).  Later, Wilson concluded that the release of VC was 
attributed to glutamate-induced cell swelling followed by opening of the aforementioned anion 
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channels (88).  Our lab found similar results in SH-SY5Y neuroblastoma cells:  glutamate 
caused release of intracellular VC, but neither intra- nor extracellular VC affected glutamate 
uptake, and does not support a heteroexchange mechanism (83). 
Investigating vitamin C regulation and its effects on behavior 
Rebec noted that extracellular VC had an effect on the behavior in rats. In electrophysiological 
studies he observed that increased extracellular VC stimulated behavior and also that 
conversely, a decrease in extracellular VC inhibited behavior (96;97). It has long been 
suggested that depressive behavior and despair is one of the earliest signs of scurvy (2). There 
is now emerging evidence in rodents and humans that VC supplements can alter behavior with 
specific reference to mood. In several studies in stressed mice (despite their ability to make VC), 
supplements of the vitamin improved behavior and synergized with the effect of fluoxetine in the 
tail suspension test, considered am appropriate test of behavioral despair (98-100). Two human 
studies also support a role for replenishing VC to improve mood and depression.  In the first, 
college students known to be very low in VC levels due to poor dietary intake had improved 
mood following VC supplements in a randomized controlled clinical trial (101). Further, 
hospitalized patients supplemented with VC at a dose of 1 gram daily had significantly improved 
mood and decreased depression compared to a matched control group of patients who received 
an identical tablet containing vitamin D. The physiologic implications of VC transport and efflux 
mechanisms are that not only VC concentrations are carefully regulated but are also important 
for molecular neuronal function, cognition and behavior. Dysregulation of VC may lead to an 
impaired neurobehavioral phenotype. One way to gain insight on VC’s role in behavior is to 
elucidate its regulation in the highly specialized region of the neuron, the synaptic terminal, 
where the biochemical signal propagation occurs. VC regulation in this region has received little 
attention. Thus, I have conducted the following studies for my thesis and investigated whether 
21 
dysregulation of VC leads to an altered neurobehavioral phenotype and also whether and how 
VC is regulated at the nerve terminal. 
 
SPECIFIC AIMS 
 
Specific Aim 1: To determine if and by what mechanism increased oxidative stress by combined 
vitamin C and E effects neuronal SVCT2 function and/or expression. 
 
Specific Aim 2: To determine if and by what mechanism increased oxidative stress effects 
vitamin C regulation at the nerve terminal.  
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CHAPTER II 
 
 
MATERIALS AND METHODS 
  
ANIMAL MODELS  
Wild type (Gulo+/+; SVCT2 +/+) 
Mice denoted as “wild-type mice” are from C57BL/6J background. These mice were originally 
obtained from Jackson laboratories (stock #000664) and a colony was maintained in-house. All 
animals were housed in tub cages in a temperature- and humidity-controlled vivarium on a 
12:12-h light:dark cycle with lights on at 6AM. All procedures conformed to Institutional IACUC 
guidelines.  Mice had free access to food and water for the duration of experiment. 
L-gulonolactone oxidase deficient mice (Gulo-/-) 
Mice heterozygous for the gulonolactone oxidase gene were originally obtained from Mutant 
Mouse Regional Resource Centers (http://www.mmrrc.org, #000015-UCD) and maintained on a 
C57BL/6J background. Gulo-/- mice are unable to synthesize VC and were supplied with 0.33g/L 
VC in their drinking water except during experimental manipulations. This supplementation level 
provides adult (non-pregnant) gulo−/− mice with approximately wild-type levels of VC in tissues 
(102;103). To minimize oxidation of VC, deionized water was supplemented with 0.01 mmol/L 
EDTA.  
Sodium-dependent Vitamin C Transport Type 2 heterozygous mice (SVCT2+/-) 
Mice that were heterozygous for slc23a2 gene that encodes for SVCT2 mice were originally 
provided by Dr. Robert Nussbaum on the 129/SvEvTac background and were backcrossed more 
than 10 generations to the C57BL/6J background as described (104).  
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L-gulonolactone oxidase and SVCT2 deficient mice (Gulo-/-; SVCT2+/-) 
To enable both systemic and intracellular VC depletion, gulo-/- mice were crossed with mice 
lacking one allele of the SVCT2 (SVCT2+/-) (67) to generate gulo-/-/SVCT2+/+ ; gulo-/-/SVCT2+/- 
and gulo-/-/SVCT2/- littermates. These were bred separately from both the Gulo+/+ and SVCT2+/+ 
groups.  
 
Genotypes of each mouse were confirmed using PCR as outlined in genotyping. 
 
All animals were housed in tub cages in a temperature- and humidity-controlled vivarium on a 
12:12-h light:dark cycle with lights on at 6AM. All procedures conformed to Institutional IACUC 
guidelines.  Mice had free access to food and water for the duration of experiment.  
 
24 
EXPERIMENTAL DIETS 
 
Table 2.1: Macronutrient compositions of experimental diets utilized in Specific Aims I-II. 
 
 Normal Chow Western Diet*  
(VE+) 
Western Diet* 
(VE-) 
Supplier Southern Agriculture Harlan Teklad Harlan Teklad 
Catalog No. 5001 TD.07310 TD.07310 
    
Macronutrient 
(% Calories Provided) 
   
        Fat 12.1 33.6 33.6 
        Protein 28.0 17.1 17.1 
        Carbohydrate 59.8 49.3 49.3 
    
        Lard -- 16 16** 
        Sucrose 3.7 34 34 
        Cholesterol  0.2 0.2 
    
        Vitamin E, IU/kg 49 50-150 0 
        Vitamin C, mg/gm 0 0 0 
    
*An atherogenic diet 
**“Vitamin-Free” Test Casein (alcohol-extracted) and tocopherol-stripped lard are used to limit 
endogenous vitamin E 
 
Normal rodent chow that contained essentially no VC and 42 IU/kg of VE (total tocopherols) (Lab 
Diet, #5001). VE-deficient and supplemented diets were custom made by Harlan Teklad 
(TD.07310 and TD.07311 respectively). Western diet (16% lard, 34% sucrose, 0.2 cholesterol), 
(TD.07310)  
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BEHAVIORAL ASSESSMENTS 
Weight 
 Scurvy in mice typically manifests after 5-6 weeks of VC deprivation (102;103) and early 
signs include weight loss. Mice were weighed on a standard gram scale twice per week and 
observed for signs of overt scurvy. 
Motor & Strength Assessments 
Gait Analysis  
Shorter stride length can be indicative of muscle weakness or ataxia. To assess this, hind-foot 
printing was performed to monitor changes in stride length. Prior to the session, non-toxic ink 
was applied to the hind paws of the mice. The mice were then allowed to walk freely along a 
narrow 5-inch corridor lined with paper. Average stride length was calculated as the distance 
between two consecutive footprints, averaged from 3 strides as described (103;104).  
Locomotor Activity  
In each 10 min session, the mice were allowed to individually explore an open 27.9 X 27.9 cm 
chamber (Med Associates, OFA-510). Locomotor activity (distance traveled and velocity) was 
automatically recorded by the breaking of infra-red beams as described (103). After each mouse 
the chamber was cleaned with 10% alcohol solution. Mice were tested in the same chamber for 
their repeated trials. 
Inverted Screen 
Mice were assessed for general muscle grip strength in the inverted screen test. In each 5 min 
trial, mice were placed on a one-centimeter wire mesh and slowly inverted completely over a 
collection box. The latency to fall was recorded for each mouse.  
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Rota-rod Activity  
All groups were tested for motor coordination on the Rota-rod.  Mice with severe coordination 
problems will have difficulty remaining on the Rota-rod even at low speeds. Performance 
generally improves across subsequent trials; therefore a training session was conducted. In each 
5 min trial, mice were placed on a ridged, rotating beam that slowly accelerated from 4 rpm to 40 
rpm. The time it took the mouse to fall was recorded. If the mice simply clung to the beam and 
rotated along with it without falling this was recorded as a ‘rotation’.  
Wire Hang  
In each 60 sec trial, mice were placed to hang by their front legs in the middle of a plastic wire 
suspended horizontally between two platforms. A score indicating the activity of the mouse is 
displayed as: 4 = stabilized itself within 30 sec; 3.5 = stabilized itself within 60 sec; 3 = attempts 
to stabilize itself but fails to do so within 60 sec; 2 = remains hanging from the wire for 60 sec; 0 
= falls from wire within 60 sec.  
Horizontal Beam  
Similar to the wire hang, in each 60 sec trial, mice were placed to hang by their front legs in the 
middle of a plastic beam suspended horizontally between two platforms. A score indicating the 
activity of the mouse is displayed as the following: 4 = stabilized itself to a four-paw grip position 
within 30 sec; 3.5 = stabilized itself to a four-paw grip position within 60 sec; 3 = attempts to 
stabilize itself but fails to do so with 60 sec; 2 = remains hanging from the beam for 60 sec; 0 = 
falls from wire within 60 sec as described (103). 
Zero Maze  
Anxiety was assessed by exploration patterns in the elevated zero maze. In each 5 min session, 
mice were placed on an elevated circular platform with two opposite quadrants enclosed and two 
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open. Mice were allowed to explore the maze and activity was recorded with an overhead 
camera and analyzed with Any-Maze computer software (Stoelting, USA).  
Y-Maze  
In each 5 min session, mice were placed in one arm of a clear Plexiglas Y-maze consisting of 
three identical arms void of visual cues. As the mouse explored the maze, the sequence of 
consecutive individual arm entries was recorded with an overhead camera. An alternation was 
recorded as a ratio of the number of three non-repeated entries divided by the total number of 
entries minus two.  
 
Behavioral Assessments and data analysis were performed in part through the use of the Murine 
Neurobehavior Core Laboratory at the Vanderbilt University Medical Center. 
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SYNAPTOSOME PREPRATIONS AND FUNCTIONAL ASSESSMENTS 
 
For all of the assessments or assays, mice were deeply anesthetized with isoflurane and killed 
quickly by decapitation.  
 
Synaptosome Preparations and Fractionation Steps (Chapter IV) 
 
 
Figure 2.1: Flowchart of Overall Synaptosome Preparation. 
 
Crude Synaptosome Preparation 
The whole cortex region of a mouse brain was dissected out on a cold block and added to 9 ml 
of homogenization buffer (0.32 M sucrose/ 4.3 mM HEPES solution, 9 µl of 1000X protease 
inhibitor cocktail (1.54 µM aprotinin, 10.7 µM leupeptin, 0.948 µM pepstatin, 200 µM PMSF)) in 
Low Spin (2X) 
1000G (10min) 
SUCROSE METHOD 
Discontinuous Gradient  
100000G (2hrs) 
P1 
CRUDE METHOD 
High Spin  
12000G (15mins) 
B3 
Cytosolic 
Pre-Synaptic 
Post-Synaptic 
FRACTIONATION 
P2 
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a 10 ml glass homogenizer tube.  The mixture was homogenized with a hand-held Teflon pestle 
(approximately 7 strokes).  The homogenate was then transferred to a 15 ml plastic tube for 
centrifugation at 1000X G for 5 min at 4°C.  The supernatant (S1) was then transferred to a 15 
ml plastic tube and then centrifuged at 12,000X G for 15 min at 4°C.  The pellet was suspended 
in assay buffer (1300 µl of Krebs-Ringer Hepes buffer (10 mM HEPES, 128 mM, 5.2 mM KCl, 1 
mM NaH2PO4, 10 mM Glucose, 2.2 mM MgSO4 1.2 mM CaCl2)) and then transferred to an 
Eppendorf tube for assays.  
Enriched Synaptosome Preparation 
Prefrontal cortex brain tissue (half or the cortex) was homogenized as above in 10 ml of 0.32 M 
homogenization buffer (0.32 M sucrose in 4.2 mM Hepes (pH 7.4), 0.1 mM CaCl2, 1 mM MgCl2, 
1.54 µM aprotinin, 10.7 µM leupeptin, 0.948 µM pepstatin, 200 µM PMSF) in a 15 ml conical 
tube. The homogenate was removed and centrifuged at 1000 g (2250 rpm) on a tabletop 
centrifuge at 4° C for 10 min to pellet nuclei and membrane debris (P1a). Supernatant was 
transferred to clean 50 ml conical tube on ice (S1a).  P1a pellets were gently resuspended in 10 
ml of 0.32 M sucrose solution the centrifugation step was repeated (P1b). Supernatant (S1b) 
was transferred to 50 ml conical tube containing S1a. The supernatant was brought 20 ml with 
0.32 M sucrose solution and centrifuged at 10,000XG at 4° C for 20 minutes to produce P2 
pellet (contains crude synaptosomes, mitochondria, and microsomes). P2 pellets were gently 
suspended in 3.4 ml of 0.32 M sucrose solution and aliquot was taken for Western blotting.  
 
The remaining suspension of P2 pellet was applied to a discontinuous sucrose gradient. This 
was prepared in Beckman 14 ml polycarbonate tubes in which 3 ml of 0.8 M, 1.0 M and 1.2 M 
sucrose solutions were slowly layered in that order. Three milliliters of crude synaptosome 
sample were layered on top of gradient and balanced with 0.32 M sucrose solution. Samples 
were then centrifuge in Beckman ultracentrifuge (Optima LE-80K) using an SW 40 Ti rotor at 
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100,000XG (23712 rpm) at 4° C for 2 hours. Enriched synaptosomes were collected from 
interface of the 1.0 M and 1.2 M solutions and transferred to clean 15 ml conical tube.  Fractions 
were diluted with 3 ml of the 0.32 M sucrose solution and centrifuged in same rotor at 
100,000XG for 30 min at 4° C. 
Synaptosome Fractionation  
Pre- and post-synaptic fractions in both enriched and crude synaptosome preparations were 
obtained by the following protocol. The P2 pellet from an enriched or crude synaptosome 
preparation was gently suspended in 4 ml hypotonic lysis buffer (Hypotonic lysis buffer: 20 mM 
Tris (pH 6.0), 0.1 mM CaCl2, 1 mM MgCl2, 1% Triton, 1.54 µM aprotinin, 10.7 µM leupeptin, 
0.948 µM pepstatin, and 200 µM phenylmethyl sulfonyl fluoride (PMSF)). This was incubated on 
ice for 20 minutes to lyse membranes and transferred to 5 ml ultracentrifuge tubes (Beckman 
Ultra Clear, catalog #344057). Samples were centrifuged at 100,000 XG (28,700 rpm) in a SW 
55 Ti rotor in a Beckman centrifuge (Optima LE-80K) for 120 minutes at 4ºC. The supernatant 
(S3), which contains cytosolic proteins from both pre- and post- synaptic terminals, was 
transferred to another tube and placed on ice. Pellet P3 was suspended in 1 ml of Tris buffer, 
pH 8.0 (Tris Buffer: 20 mM Tris (pH 8.0), 1% Triton X-100, 1.54 µM aprotinin, 10.7 µM leupeptin, 
0.948 µM pepstatin, and 200 µM PMSF). This was transferred to plastic 2 ml Eppendorf tubes 
and incubated on ice for 20 minutes. The samples were centrifuged at 10,000XG for 30 minutes 
at 4ºC, then the supernatant (S4) containing the presynaptic fraction was transferred to 
Eppendorf tubes. The pellet (P4) was suspended in 200 µl of 1x PBS/1% SDS and centrifuged 
at 10,000XG for 30 minutes to obtain the supernatant (S5) containing the post-synaptic fraction, 
as described in Figure 2.2.  
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Concentration of cytosolic/perisynaptic and presynaptic fractions 
To ensure adequate amounts of protein were studied, samples were concentrated using 3K 
concentrator tubes (Amincon Ultra, Millipore) that were centrifuged at 3400 rpm at 4°C until 
volumes reach ~250 µl. Once the correct volume was reached, membranes were washed with 
homogenization buffer, and transferred to new Ependorff tubes for assays. 
 
 
Figure 2.2: Flowchart of Synaptosome Fractionation.  
 
Fura Red-AM Assay  
Crude synaptosome preparations were centrifuged at 13,000 rpm for 2 min at 4°C to pellet 
synaptosomes.  The pellet was then suspended in 1300 µL of the Fura Red-AM (Invitrogen, 
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F3021) solution (1300 µL of assay buffer with glucose and 5.3 µL of 1 mM Fura Red-AM dye).  
The mixture was then incubated in a 37°C bath for 30 minutes and centrifuged again at 13,000 
rpm for 2 min at 4°C. The supernatant was removed and the pellet was suspended in 1300 µL 
of the assay buffer with glucose. Following this, 50 µL of the preparation treated as noted in text 
at 37°C. At the end of each incubation period samples were treated with 1 mL of ice-cold assay 
buffer (-glucose), centrifuged at 13,000 rpm for 2 min at 4°C, and the supernatant discarded. 
This was followed by addition of 250 µL of 60% methanol in water to lyse the synaptosomes. 
After a brief centrifugation to clear undissolved material, 100 µL aliquots were transferred to a 
clear plate in a microtiter plate reader and fluorescence was read at excitation 420/emission 610 
nm. 
 
BIOCHEMICAL ASSESSMENTS  
Tissue Preparations and Assays 
If fresh tissues were not needed, cortex, cerebellum and liver were removed and frozen in dry-ice 
and stored at -80 °C until needed.  
Protein determination  
The Pierce BCA Protein Assay Kit (Thermoscientific Cat No. 23225) is based on bicinchoninic 
acid (BCA) and allows for the colorimetric detection and quantitation of total protein within a 
tissue sample. Prior to determination assay, tissues were homogenized with a rubber policeman 
in RIPA buffer (10 mM Tris-Cl (pH 8.0),1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% 
sodium deoxycholate, 0.1% SDS, and 140 mM NaCl). According to the manufacturer’s 
instructions, 2.5 µL of the unknown protein sample was added to a 96-well microplate. The assay 
working reagents (Reagent A and Reagent B) were mixed in a 1:50 ratio and 200 µL was added 
to each well. A bovine serum albumin (BSA) standard curve (0, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0 
33 
µg/ml) was also added to the plate. The plate was covered in Parafilm and incubated in a 37°C 
bath for 10min. After cooling to room temperature the plate was then read with a 
spectrophotometer at an absorbance of 562 nm. 
Western blot analysis 
Appropriate amounts of protein samples were mixed with 4X Sample Buffer and loaded into a 
well on a gel (5-20 µg total protein per lane) along with a Kaleidoscope Precision Plus Protein 
Standard (Bio- Rad). Samples were subjected to denaturing electrophoresis on a 7.5% 
acrylamide gel. Protein samples were transferred Immobilon PVDF membrane (pore size 0.45), 
according to the manufacturer’s instructions (Millipore). Membranes were blocked in blocking 
buffer (5% BSA or dry milk, 0.5% Tween 20) for 1-hour at room temperature or overnight at 4°C. 
Membranes were then incubated with primary antibodies (diluted 1:200-1000) in blocking buffer 
at 4 °C with gentle rocking overnight. Blots were washed (3 times for 10 min each) at room 
temperature in TBS-T (Tris-Buffered Saline; 150 mM NaCl, 20 mM Tris pH 7.5 with 0.5% (v/v) 
Tween 20; Sigma Aldrich; St. Louis, MO). Then, blots were incubated with species-specific 
horseradish peroxidase (HRP)-conjugated secondary antibody (diluted 1:10000) in blocking 
buffer for 1-hour at room temperature and subsequently, washed in TBS-T (3 times for 10 min). 
Antibody detection was performed with Western Lightening Plus-ECL Enhanced 
Chemiluminescence Substrate Kit (Perkin Elmer) and Carestream Kodak BioMax MR Film 
(Kodak, Rochester, NY). Band intensity from X-ray film detection was analyzed by densitometry 
using ImageJ software from the National Institutes of Health.  
Primary antibodies used for immunoblotting are the following: SVCT2 (S-19), VMAT2 (H-90), 
Actin (I-19), (all from Santa Cruz Biotechnology). GAPDH (Milllipore, MAB-374), NMDAR1 (BD 
Pharmingen, 556308), PSD-95 (Neuromab, 75-028), GβP (Santa Cruz, SC-378) for the 
synaptosome fractionation studies were kindly provided by Katherine Betke in Dr. Heidi Hamm’s 
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laboratory (Vanderbilt University). Secondary antibodies used at a 1:10000 dilution for 
immunodetection are the following: anti-rabbit IgG HRP and anti-goat IgG HRP conjugate 
purchased from Santa Cruz Biotechnology. 
Genotyping 
Tail clippings were added to 100 µL extraction buffer and 25 µL tissue buffer. Samples were 
incubated 20 minutes at room temperature and then 3 minutes at 95°. The reaction was stopped 
with the addition of 100 µL neutralization buffer. Each PCR reaction contained 10 uL PCR 
Master Mix, 2 µL RNA/ DNAase free water, 1 µL of each primer according to gene probe (SVCT 
2 or Gulo). Samples were processed in DNA Engine® Peltier Thermal Cycler (Bio-Rad). 10 µL 
of sample was loaded in each well and run on 1.5% agarose gel (1.5 g agarose, 100 ml 1X TAE, 
and 10 µL Ethidium Bromide) at 95V for 30mins.  
Primers were purchased from Integrated DNA Technologies (Coralville, IA) 
Gulo Primer 1:  5’- CGC GCC TTA ATT AAG GAT CC -3’ 
Gulo Primer 2:  5’- GTC GTG ACA GAA TGT CTT GC -3’ 
Gulo Primer 3:  5’- GCA TCG CAG TGA CTA AGG AT -3’ 
 
SVCT2 Primer (50):  5’- CAT CTG TGC GTG CAT AGT AGC -3’ 
SVCT2 Primer (51):  5’- CAC CGT GGC CCT CAT TG -3’ 
SVCT2 Primer (54):  5’- TCT GAG CCC AGA AAG CGA AG -3’ 
SVCT2 Primer (55):  5’- GAT GGA CGG CAT ACA AGT TC -3’ 
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Antioxidant Analysis  
Vitamin C 
In both chapters, VC was measured as ascorbic acid in metaphosphoric acid extracts of tissues 
as described (103) using ion-pair HPLC with electrochemical detection.  
Vitamin E  
In both chapters, VE was measured as α-tocopherol in extraction buffer containing reagent 
alcohol, 10 mg/ml butylated hydroxytoluene, 3% SDS and hexane and subjected to HPLC 
analysis as described (105).  
Reduced glutathione 
Vitamin C tissue extracts were used to also measure reduced glutathione by an adaptation of the 
o-phthalaldehyde method as described (106). Data for all assays were expressed per gram 
tissue weight (wet weight). 
 
Oxidative Stress Analysis  
Malondialdehyde  
To assess lipid peroxidation, malondialdehyde was measured by homogenizing samples in 5% 
TCA solution and reacted with thiobarbituric acid as described (106). 
F4-neuroprostanes and F2-isoprostanes  
Tissue contents of esterified F4-neuroprostanes and F2-isoprostanes were quantified by stable 
isotope dilution negative ion chemical ionization gas chromatography/mass spectrometry (107). 
These analyses were performed in the Vanderbilt University Eicosanoid Core Laboratory. 
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STATISTICAL ANALYSIS  
 
Behavioral Data: (Chapter III)  
In Experiment 1, for all assessments that were conducted at both time points, repeated 
measures ANOVA was conducted with Time as the repeated variable (Test 1, Test 2) and 
vitamin C status (VC+, VC-) and vitamin E status (VE+, VE-) as the between groups variables. 
For the inverted screen test an univariate ANOVA was conducted with vitamin C status (VC+, 
VC-) and vitamin E status (VE+, VE-) as the between groups variables. In Experiment 2, 
Repeated measures ANOVA were conducted with Time as the repeated variable (Test 1, Test 2, 
Test 3) and genotype of the gulonolactone oxidase gene (gulo+/+, gulo-/-) and vitamin C 
transporter (SVCT2+/+, SVCT2+/-) as the between groups variables.  
 
Biochemical and oxidative stress markers: (Chapter III, In Experiment 1) 
Univariate ANOVA was conducted for each independent measure with vitamin C status (VC+, 
VC-) and vitamin E status (VE+, VE-) as the between groups variables. In Experiment 2, 
univariate ANOVA was conducted with genotype of the gulonolactone oxidase gene (gulo+/+, 
gulo-/-) and transporter (SVCT2+/+, SVCT2+/-) as the between groups variables.  
 
A P-value of < 0.05 was considered statistically significant. Significant results from the omnibus 
ANOVA were followed by the Bonferroni–corrected pairwise comparisons and are reported in 
the text with interaction effects denoted as factor X factor. Due to the limitations of the statistical 
tests performed, in each experiment direct comparisons between the control groups and the 
double deficient group (VC+VE+ and VC-VE- or Gulo+/+/SVCT2+/+ and Gulo-/-/SVCT2+/-) could 
not be assessed. Figures indicate significant differences between group variables noted in their 
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respective figure legend. All statistical analyses were performed by IBM SPSS Statistics 
Software (Version 19). 
 
38 
CHAPTER III 
 
COMBINED VITAMIN C AND E DEFICIENCY INDUCES MOTOR DEFECTS IN 
GULO−/−/SVCT2+/− 
 
Adapted from Pierce, M. R., DiAsio, D. L., Rodrigues, L. M., Harrison, F. E., & May, J. M. (2013). 
Combined vitamin C and E deficiency induces motor defects in gulo−/−/SVCT2+/− mice. 
Nutritional Neuroscience, 16(4), 160-173. 
 
INTRODUCTION 
 
Oxidative stress is a key feature of normal aging, and is markedly increased in stroke and certain 
neurodegenerative conditions. Neurons are especially prone to oxidative stress due to their high 
metabolic activity (49). Chief among the central nervous system’s defenses against oxidative 
stress are low molecular weight antioxidants such as vitamins E and C. VE (mostly α-tocopherol) 
is lipid-soluble and provides protection in cellular membranes. Vitamin C (VC) is water-soluble 
and is transported from blood into the cerebrospinal fluid (CSF) and from the CSF in ventricles 
into neurons by the Sodium-dependent Vitamin C Transporter – type 2 (SVCT2) (61). This 
transporter is responsible for generating VC concentrations up to 2-6 mM in neurons (53). Mice 
that are homozygous for the SVCT2 gene deletion die shortly after birth with undetectable VC 
levels in the brain (67). This demonstrates the importance both of VC content and regulation by 
SVCT2 in brain.  
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In vitro (108) and in vivo (19) studies have demonstrated a synergistic relationship between VC 
and VE that helps to preserve neuronal function and survival (21). Guinea pigs, like humans, are 
unable to synthesize VC and have long served as a model for study of both VE and VC 
deficiencies. Using this model, it was demonstrated that first, high dietary fat and cholesterol 
exacerbated chronic VC deficiency by both decreasing VC levels and increasing its oxidation 
ratio (109). Second, a diet deficient in both vitamins had greater oxidative stress than animals 
deficient in either vitamin alone (19). Lastly, the doubly deficient animals developed a phenotype 
of progressive paralysis and death due to neuronal and fiber loss in the long tracks of the spinal 
cord (20). This severe phenotype precluded further studies with guinea pigs.  
 
To develop a more tractable model that could also be genetically manipulated, we have adapted 
the double vitamin deficiency model to gulo-/- mice. These mice lack functional gulonolactone 
oxidase (gulo) (102), which is required for VC synthesis. VC tissue levels in these mice can be 
readily manipulated by dietary means (102;103). VE can also be removed from their diets, thus 
yielding a combined VC and VE deficient model for whole-body oxidative stress. In addition to 
decreasing dietary antioxidants, we also increased fat and sucrose components, as both of these 
dietary factors have also been shown to increase oxidative stress (110;111). This model is 
physiologically relevant because humans deficient in one vitamin are often marginal in the other. 
Furthermore, those most likely to have VC deficiency tend to eat a diet low in fruits and 
vegetables (112;113) and high in triglycerides and cholesterol. 
  
The purpose of this study was to determine the effect of oxidative stress due to combined VC 
and VE dietary deficiency on the neurological phenotype of mice. The first experiment induced 
both single and double vitamin deficiencies then assessed the subsequent impact on motor and 
cognitive skills in gulo-/- mice. The second experiment, designed to establish a more severe 
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oxidative stress and specifically deplete intracellular VC, induced double vitamin deficiency in 
gulo mice that also lacked one allele for the SVCT2 and included further behavioral testing. 
 
PILOT STUDY  
 
Our laboratory initially developed the double-deficient model of neurological damage in guinea 
pigs, as noted above. The double-deficient diet was adapted to mice with the goal of developing 
a sustainable oxidative stress to assess responsiveness of the SVCT2 expression and 
distribution. Since the SVCT2 determines VC localization, the goal was to determine how the 
brain responds to combined VC deficiency and oxidative stress due to lower dietary antioxidants 
in terms of VC distribution and function. A pilot study was conducted to determine the optimal 
time for the vitamin deficiencies since the combined VE and VC deficient diet should produce 
more oxidative stress than the VE deficient diet alone.  
 
In contrast to guinea pigs, mice can synthesize VC. Therefore, in the mouse double-deficient 
model, all mice have targeted deletion of gulonolactone oxidase (Gulo-/-). This enzyme catalyzes 
the last step in the synthesis of VC and is missing in humans and guinea pigs. When mice were 
not on an experimental diet they were supplemented with VC (0.33 g/L) in their drinking water 
(~2.5 mg/mouse), which provided levels equal to wild-type control. Treatments were made in 
de-ionized water with 0.01 M EDTA to increase VC stability. 
 
To establish the mouse double-deficient model, five week-old Gulo-/- mice were placed on a VE 
and VC deficient diet (Harlan Teklad, diet #TD88163). Gulo-/- mice that are not provided VC 
supplementation develop scurvy in about 4-5 weeks (102). Therefore, 3 weeks of VC deficiency 
was chosen to ensure low VC levels but to avoid scurvy. Mice are relatively resistant to VE 
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deficiency, requiring more than 10 months on a solely VE-deficient diet before they develop 
symptoms including shaking of the head and ataxia.  Therefore, 2, 4, and 6 months of VE 
deficiency was the time-points chosen as assessment points which were then followed by the 
complete removal of VC.  
 
Table 3.1 shows that both VC and VE were decreased to levels about 10% of normal in brain 
cortex and liver by the diets. The formation of malondialdehyde (MDA) was measured to assess 
lipid peroxidative stress in these mice. Cortex MDA levels were increased at both 2 and 4 
months of VE deficiency.  Liver MDA levels were increased at all time points.  These results 
confirm increased oxidative stress in these mice.  Liver F2-isoprostane levels showed a similar 
trend and further indicate increased oxidant stress generation. Because there was no significant 
increase in MDA at 6 months and since there was weight loss observed in the 6 month group 
before VC was removed, we concluded 6 months was not optimal and focused on the 2 and 4 
month groups, which both had increased MDA levels in cortex and liver. Between these two 
groups there were more motor defects in the 4-month group. In wild-type C57/B6 adult mice (20 
g female; 25 g male) stride length is ~58 mm (103). However, in my study, gait was adversely 
affected in the combined VC and VE group. In the 2 month group the average gait length was 
~46 mm in the control group and ~36 mm in the 4 month group. Locomotor activity was normal 
for age and strain; there was no difference between 2 and 4 months indicating that they were 
not grossly affected by scurvy. Therefore, I concluded that 4 months was the optimal time for 
VE-deficiency.  
 
These data demonstrate that combined dietary depletion of the two vitamins in mice unable to 
make VC causes detectable behavioral changes associated with increased oxidant stress in 
brain cortex. These results also demonstrate the feasibility of using this in vivo model of oxidant 
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stress in the planned studies to assess the contribution of each vitamin to the induced oxidative 
stress as described in the next section. 
 
Table 3.1: Pilot Study - Summary of the effects of combined Vitamin C and E deficiency 
on experimental mice groups.  
All four experimental groups were subjected to 0,2,4 or 6 months of vitamin E deprivation 
followed by 3 weeks of vitamin C deprivation. Assessment values shown for groups were 
normalized to the Gulo+/+ (wild-type) had normal amounts of vitamin E in their diets. Normal 
Gulo+/+ 0 MON values are represented as “++++” while other groups are shown with variable 
numbers of pluses relative to normal. Relative biochemical assessments of the groups, 
including vitamin C, vitamin E, MDA, F2- Isoprostanes and F4- Neuroprostanes concentration, 
are shown for cortex and liver tissues. Also shown, are relative group performance values for 
several motor coordination tests. A comprehensive display of the data can be found in  
Appendix 1. 
 
 
 
  
  Vitamin E Deprivation Time 
  0 MON 2 MON 4 MON  6 MON 
      
BIOCHEMICAL Cortex Concentration     
ASSESSMENTS          Vitamin C  ++++ + + + 
          Malondialdehyde     ++++ ++++++ ++++++ ++++++ 
          F2- Isoprostanes ++++ ++++++ ++++++ ++++++ 
          F4- Neuroprostanes ++++ ++++ ++ ++ 
      
 Liver Concentration     
          Vitamin E ++++ + + + 
           Malondialdehyde ++++ +++++++ +++++++ +++++++ 
           F2- Isoprostanes ++++ ++++++++ ++++++++ ++++++++ 
      
      
BEHAVIORAL 
ASSESSMENTS 
Motor-Coordination 
Performance 
    
          Ambulatory Distance ++++ ++++ ++++ +++++ 
          Ambulatory Velocity ++++ ++++ ++++ ++++ 
          Inverted Screen ++++ ++++++ ++++++ +++++ 
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EXPERIMENTAL DESIGN AND BEHAVIOR ASSESSMENT SCHEDULE 
 
Experiment 1 Design:  
Male and female gulo-/- mice were maintained on a normal rodent chow that contained 
essentially no VC and 42 IU/kg of VE (total tocopherols). At 4-5 weeks of age, the mice were 
randomly divided into four groups on a Western diet (16% lard, 34% sucrose, 0.2 cholesterol). 
This was to increase oxidative stress and to provide a physiologic condition relevant to humans, 
as those deficient in these vitamins are likely to also consume a diet high in saturated fats and 
sucrose.  
 
The four treatment groups each consisted of 16 weeks of VE treatment via diet followed by 3 
weeks of VC treatment via water supplementation: (1) control group - VE treatment as 150 IU/kg 
with continued supplementation of VC at 0.33 g/L; VE+VC+ (N=9), (2) VC deficient group - VE 
treatment as 150 IU/kg and a final VC treatment of 0 g/L; VE+VC- (N=8), (3) VE deficient group - 
VE treatment as 0 IU/kg with continued VC supplementation of 0.33 g/L; VE-VC+ (N=6), and (4) 
doubly deficient group - VE treatment as 0 IU/kg with a final VC treatment 0 g/L VE-VC- (N=8). 
The four groups, containing approximately equal males and females, are shown in Experimental 
Scheme 1 (Figure 3.1). 
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Figure 3.1: Experimental Scheme 1, Combined vitamin C & E deficient diets. 
Mice started VE treatments at 4-5 weeks of age with continued VC supplementation. After 16 
weeks of VE treatments mice were tested (Test 1) to observe changes in behavior. VC 
treatment lasted 3 weeks, after which another set of behavior tests were performed (Test 2). 
Mice were then sacrificed for biochemical analysis. 
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Experiment 1 Behavior Assessment Schedule: 
Experiment 1: To determine the effect of VE deprivation only, an initial behavior assessment 
(Test 1) was conducted after 16 weeks of the respective VE treatments.  A second assessment 
(Test 2) was performed after 3 weeks of the respective VC treatments to determine the effect of 
the combined vitamin deficiency, as shown in Experimental Scheme 1. Each assessment 
spanned two consecutive days. Day one included a Rota-rod training session to acclimate the 
mice to the task. Day two included gait testing, locomotor activity, inverted screen, and the Rota-
rod test session.  
 
Experiment 2 Design:  
To enable both systemic and intracellular VC depletion, gulo-/- mice were crossed with mice 
lacking one allele of the SVCT2 (SVCT2+/-) to generate gulo-/-/SVCT2+/- mice. Additional groups 
assessed included two single mutant genotypes (gulo-/- and SVCT2+/- mice), as well as wild- type 
C57BL/6J mice (gulo+/+/SVCT2+/+).  
 
At 4-5 weeks of age, all mice were placed on the VE-deficient, Western diet (TD.07310) and 
were provided with 0.33 g/L VC in their drinking water for 16 weeks. The mice were then all 
deprived of VC for 3 weeks before sacrifice.  Thus, the four groups containing approximately 
equal males and females were wild-type control; gulo+/+/SVCT2+/+ (N=10), Gulo; gulo-/-/SVCT2+/+ 
(N=5), SVCT2; gulo+/+/SVCT2+/- (N=9) and gulo/SVCT2; gulo-/-/SVCT2+/- (N=10) as shown in 
Experiment Scheme 2 (Figure 3.2). 
46 
 
 
  
 
Figure 3.2: Experimental Scheme 2, Combined vitamin deficiency effects on gulo-/- SVCT2 
+/- mice.  
Mice started VE deprivation at 4-5 weeks of age with continued VC supplementation. After 16 
weeks mice were tested (Test1) to observe changes in behavior. VC treatment lasted 3 weeks, 
after which another set of behavior tests were performed after 2 weeks and followed-up with 
another at 3 weeks (Test 2 and 3 respectively). Mice were then sacrificed for biochemical 
analysis. 
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Experiment 2 Behavior Assessment Schedule: 
This experiment was designed to confirm the findings from experiment 1 and expand the results 
to include three additional genotypes. The first assessment (Test 1) was done at 16 weeks after 
VE deficient diet followed by two separate assessments at weeks 2 and 3 of the VC treatment 
phase which corresponds to 18 and 19 weeks of VE deficiency, (Test 2 and Test 3, respectively), 
as shown in Experimental Scheme 2. Each assessment spanned two consecutive days with the 
more energy demanding tasks on day 2. Day one included one session of locomotor activity, 
zero-maze, inverted screen, and Rota-rod training, sequentially. Day two included one session of 
gait, Y-maze, horizontal beam, wire-hang, and Rota-rod test, sequentially.  
 
All behavioral tests were performed under similar lighting. Repeated testing of cohorts was 
performed at the same time of day (morning or afternoon).  
 
RESULTS  
Experiment 1 - Combined vitamin C & E deficiency in Gulo-/- mice 
Body Weight and general appearance 
As expected, the weights of all mice increased with age. During VC deprivation all the groups 
except for the control decreased slightly (P<0.01); however, there were no significant interaction 
effects with time for the groups (P= 0.56) (Figure 3.3A). There were no physical signs of early 
scurvy in any of the mice following VC removal (hair loss, hunched posture, or lethargy).   
Behavioral Assessment  
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Gait analysis for changes in stride length showed no main effects of time, VE or VC status, and 
no VE X VC, or Time X VE interactions (P’s>0.062). There were, however, significant interaction 
effects of Time X VC and of Time X VC X VE (P’s<0.038) (Figure 3.3B). Follow-up analyses 
showed that the VE+VC- group was the only group to show altered gait with time, with a 
decreased stride length between test 1 and test 2 (P<0.01). At test 1, VE+VC- mice had a slightly 
longer gait than VE+VC+ mice (P<0.05), but at test 2 the direction of this difference was reversed 
(P<0.05).   
  
As expected, the distance traveled during locomotor activity testing decreased at least 35% in 
test 2 in all groups indicating normal habituation to the chamber as supported by the main effect 
of Time (P<0.01) (Figure 3.3C). Both VC deficient groups (indicated by the dashed lines) 
explored less than the VC-supplemented groups at test 2 (P<0.01) (Figure 3.3C). Compared to 
the control group (VE+VC+), all of the mice maintained similar locomotor velocity during both test 
sessions except for the VE+VC- group, which decreased in test 2 as evident from an interaction 
effect of Time X VC X VE (P<0.01) (Figure 3.3D). Follow-up analyses confirmed a significant 
effect of time in the VE+VC- group (P<0.01) but not in any of the other groups (P’s> 0.181).  
 
On the inverted screen, both of the single and double vitamin deficient groups had shorter 
latencies to fall than the VE+VC+ group. There was a main effect of VC status (P<0.01) (Figure 
3.3E). Results in Figure 3.3F are from the Roto-rod probe trial only (day 2 of each 2-day test 
session). VE deprivation alone did not lead to any differences among the groups in latency to fall 
from the rod (Test 1).  All of the groups maintained their performance over time; however, the VC 
deficient groups had lower baseline level of performance as shown by a shorter latency to fall at 
both testing points compared to VC supplemented mice (P<0.01) (Figure 3.3F).     
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Figure 3.3: Behavioral phenotype of combined vitamin C & E deficiency. 
Behavioral assessments included changes in body weight (A) stride length (B) locomotor activity 
(C) and motor coordination on the Rota-rod (D) Displayed are group means ± standard error of 
means.  
^ Denotes a significant difference between Test 1 and Test 2 
* Denotes a significant difference between the respective VC+ and VC- groups for Test 2 
(p<0.05) 
# Denotes a significant difference between VC+ and VC- groups over time 
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VC and α-Tocopherol measurements of brain cortex, and liver  
VC and α-tocopherol were measured in both brain and liver to determine the effectiveness of 
deprivation treatments. The liver was studied to reflect whole body VC status, since it receives 
dietary VC from the portal system and does not synthesize the vitamin in gulo-/- mice. As 
expected, VC deprivation for 3 weeks regardless of VE treatment lowered the VC contents of 
cortex and liver. In cortex, VC levels decreased 86% in VE+VC- and VE-VC- groups compared to 
the VE+VC+ group (P<0.01) (Figure 3.4A).  Liver VC decreased 73% and 78% in the VE+VC- 
and VE-VC- groups, respectively (Figure 3.4B). In addition to the main effect of VC status 
(P<0.01) and VE status (P<0.05), there was also interaction between the two factors (P=0.038) 
in liver. Pairwise comparisons revealed that in addition to the decreased VC in liver of both 
groups of VC-deprived mice (P’s<0.05), VE deprivation without VC deprivation lowered VC in 
VE-VC+ compared to VE+VC+ (P<0.05). 
 
As expected, VE deprivation for 16 weeks lowered α-tocopherol in cortex (Figure 3.4C) and liver 
(Figure 3.4D). In cortex, there were main effects of both VC (P<0.05) and VE (P<0.01) status, 
with no significant VC X VE status interaction (P=0.356). In liver, there were main effects of VE 
and VC deprivation (P’s<0.01). A significant VC X VE status interaction in liver (P=0.01) 
indicated that although deprivation of either vitamin led to decreases in liver α-tocopherol levels 
compared to control (P’s<0.01), no differences were found in VE- groups according to VC status 
or in VC- groups according to VE status (P’s>0.27). Thus, deprivation of either vitamin led to a 
significant decrease in α-tocopherol levels in liver. In both tissues, VE was decreased in mice 
deficient of VC by at least 80% (P<0.01). VE-VC- decreased 88% and 97% in cortex and liver 
tissue, respectively. 
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Measures of oxidative stress 
Diets did not affect GSH contents in cortex or liver (P’s>0.448) (Figure 3.4E and F). MDA levels 
in cortex and liver were increased in the VE-VC- group compared to the groups with normal VE 
intakes (Figure 3.5A and B). VC deprivation increased MDA in the cortex (P<0.05). In liver there 
was an increase in MDA following removal of both VC (P<0.01) and VE (P<0.01), with no 
interaction between the groups (P=0.547). F2-isoprostanes increased almost 3-fold in cortex in 
groups deprived of VE compared to groups on adequate VE (P<0.01; Figure 3.5C). F2-
isoprostanes, derived from non-enzymatic peroxidation of arachidonic acid, were also increased 
in cortex to a lesser extent with VC deprivation, leading to a main effect of VC status (P<0.05). A 
similar result was observed in liver with VE-VC+ and VE-VC- group levels 7-fold higher than 
controls. This was reflected in a main effect of VE (P<0.01). However there was no main effect of 
VC status (Figure 3.5D). F4-neuroprostanes, derived from peroxidation of docosahexaenoic acid, 
were about 30-fold higher than those of F2-isoprostanes (compare Figure 3.5C to 5E).  Similar to 
F2-isoprostanes, VE deprivation increased F4-neuroprostanes in cortex (P<0.05) (Figure 3.5E).  
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Figure 3.4: Combined vitamin C & E deficiency decreases antioxidant levels in cortex and 
liver. 
Biochemical assessment included measurements of VC in cortex (A) and liver (B) and 
glutathione (GSH) in cortex (C) and liver (D).  
* Denotes a significant difference between the respective VC+ and VC- groups (p<0.05) 
† Denotes a significant difference between VE+ and VE- groups (p<0.05) 
# Denotes a significant difference between the two diet groups indicated with brackets (p<0.05) 
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Figure 3.5: Vitamin E deficiency induces oxidative stress.  
Biochemical assessment included measurements of malondialdehyde in cortex (A) and liver (B); 
F2- isoprostanes in cortex (C) and liver (D); and F4- neuroprostanes in cortex (E).  
* Denotes a significant difference between VC+ and VC- groups (p<0.05) 
† Denotes a significant difference between VE+ and VE- groups (p<0.05) 
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Experiment 2 - Combined vitamin C & E deficiency in gulo-/-/SVCT2+/- mice 
In Experiment 2, a cellular VC deficiency was added to the systemic VC deficiency, using gulo-/- 
mice that had been crossed with mice heterozygous for the VC transporter SVCT2 (SVCT2+/-). 
All mice were on the same Western diet and were deprived of VE for 16 weeks, followed by VC-
deficient intakes as described for Experiment 1. This experiment was designed to confirm the 
effects observed in the VC- and E-depleted gulo-/- mice in Experiment 1 and to expand motor 
testing by adding further tests (wire hang, horizontal beam), an anxiety task, and also 
biochemical assessments of cerebellum to relate the behavioral phenotype to a brain region 
most associated with motor coordination. 
 
Body Weight and general appearance 
Weights of all mice increased with age at the time points measured and there were no 
differences between the groups (Figure 3.6A).  None of the mice had overt signs of severe 
scurvy, although gulo-/-/SVCT2+/- mice lost weight following 3 weeks of VC deficiency (P<0.01). 
Behavioral Assessment  
Changes in behavioral phenotype were observed during the last 3 weeks of the diet treatments. 
Mice were assessed both under normal VC supplementation (Test 1) and after 2 (Test 2) and 3 
(Test 3) weeks of VC deprivation (Experimental Scheme 2, Figure 3.2). 
 
There was a significant main effect of time on gait as stride length of all the groups tended to 
decrease by week 3 compared to weeks 1 and 2 (P<0.01) (Figure 3.6B). There was a main effect 
of SVCT2 genotype (P<0.05), but not of gulo genotype (P=0.17), and also a Gulo X SVCT2 
interaction (P<0.05). Therefore, stride length was shorter in gulo-/-SVCT2+/- than in 
gulo+/+SVCT2+/- mice, but there was no effect of gulo genotype in SVCT2+/+ mice. Similarly, 
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lacking one allele for SVCT2 shortened stride length in gulo-/- mice but did not affect gait in 
gulo+/+ mice. The greatest changes in stride length were thus seen in gulo-/-/SVCT2+/- mice. There 
were no other interactions among the factors of Time, Gulo and SVCT2 (P’s>0.38).  
 
Analysis of locomotor activity revealed significant main effects of time, both gulo and SVCT2 
genotype and a Time X Gulo interaction (P’s<0.05) (Figure 3.6C). However, these effects were 
all subsumed by a significant 3-way interaction among the factors (Time x Gulo X SVCT2, 
P<0.01). All mice explored less across test sessions (P’s<0.01) except the gulo+/+SVCT2+/- mice 
(P=0.32). There was no clear pattern of differences among the groups across the first two testing 
sessions. At test 3, when the greatest differences were expected, the gulo-/-SVCT2+/- genotype 
combination again had the greatest effect on behavior as these mice explored less than the other 
groups (P’s<0.05). The Time X Gulo X SVCT2 interaction for locomotor velocity (P<0.05) 
showed only that the gulo-/-SVCT2+/- were faster than the other groups during test 1 (supporting 
the greater distance travelled at this time point). There were no other velocity differences among 
the groups. 
 
On the inverted screen test, there was a Time X Gulo X SVCT2 interaction (P<0.05), although 
there were no main effects of any of the individual factors of time, or gulo or SVCT2 genotype 
(P’s>0.1) (Figure 3.6D). Across the test sessions, Gulo-/-SVCT2+/- mice showed progressively 
shorter fall latencies (P<0.01), whereas the other groups either improved or showed no change.  
 
As expected, the wild type, gulo-/-, and SVCT2+/- groups improved or maintained latency to fall or 
first rotation with training on the Rota-rod from test 1 to test 2 despite VC deprivation in the gulo-/- 
group (Figure 3.6E).  During this period a decrease in fall latency was observed in the gulo-/-
/SVCT2+/- group. There was interaction of Time X Gulo X SVCT2 (P<0.05). The gulo-/-/SVCT2+/- 
group was the only group that performed more poorly on the Rota-rod across 3 weeks of VC 
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deprivation (P<0.01). This group also demonstrated shorter fall latencies compared to other test 
groups at the final session (P’s<0.05). Gulo+/+/SVCT2+/- also performed more poorly than 
Gulo+/+/SVCT2+/+ control mice on day 3 (P<0.05) supporting the role of SVCT2 genotype in 
performance of the Rota-rod task under these conditions.  
 
Horizontal beam results produced a similar pattern (Figure 3.6F), with a Time X Gulo X SVCT2 
interaction (P<0.01) for test score. Again, the gulo-/-/SVCT2+/- mice were the only group to show 
diminishing performance across test sessions (P<0.01), these mice also performed more poorly 
than the other three groups at Test 3 (P’s<0.01). Although a similar trend was observed in the 
wire hang test (Figure 3.6G), the differences did not reach statistical significance. There were 
main effects of SVCT2 genotype (P<0.01) because the SVCT2+/- mice performed more poorly 
(higher scores) than wild-type mice, and of Time (P<0.05) because overall scores diminished 
over the test session. Although this latter result was likely driven by the poorer performance of 
the gulo-/-SVCT2+/- mice, all other interactions between the factors were non-significant 
(P’s>0.062) (Figure 3.6G). Together, these results point to consistent deficits in motor and 
coordination skills in the gulo-/-/SVCT2+/- mice. 
 
A decrease in locomotor activity could also indicate increased anxiety. However, there were no 
significant differences in the in the percent of time mice in each group spent in the open arm of 
the zero maze indicating no evidence of increased anxiety (Figure 3.6H). Alternation behavior in 
the Y-maze was normal, and did not differ according to genotype (60%-65% alternation for each 
group; P>0.05), indicating intact spatial working memory on this task in all groups of mice (results 
not shown). However, the total number of arm entries was lower in gulo-/-/SVCT2+/- group, 
consistent with their decreased tendency to explore (Figure 3.6C). 
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Figure 3.6: Genetic modification of gulo-/-/SVCT2+/- alters behavioral phenotype. 
Behavioral assessments included changes in body weight (A) stride length (B) locomotor activity 
(C) and motor coordination including inverted screen (D) Rota-rod (E) horizontal beam (F) wire 
hang (G) and zero-maze (H). 
* Denotes a significant difference between gulo+/+ and gulo-/- groups (p<0.05) 
† Denotes a significant difference between SVCT2+/+ and SVCT2+/- groups (p<0.05) 
# Denotes a gulo X SVCT2 interaction effect (p<0.05)  
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Vitamin C & E content of brain cortex, cerebellum and liver 
The VC content of cortex, cerebellum and liver tissues was decreased in gulo+/+/SVCT2+/- mice 
compared to wild-type (gulo+/+/SVCT2+/+) mice, despite the fact that these mice can synthesize 
their own VC.  As in Experiment 1, placing gulo-/- mice on a VC-free diet for 3 weeks decreased 
VC in each tissue type by 95%, 85% and 87%, respectively. In the cortex, overall VC was lower 
in gulo-/- compared to gulo+/+ mice (P<0.01), and lower in SVCT2+/- compared to SVCT2+/+ mice 
(P<0.05). There was also an interaction between Gulo X SVCT2 (P<0.05) because VC was 
decreased in all SVCT2+/- mice. Similarly, in gulo-/- mice, there was no further effect of SVCT2 
genotype on VC level (P=0.93), but being heterozygous for SVCT2 did lead to lower VC in gulo+/+ 
cortex (P<0.05) (Figure 3.7A). Further, in cerebellum, there was a main effect of both gulo 
(P<0.01), and SVCT2 status (P<0.01), while the interaction effect between the two genotypes 
was not significant (P=0.073) (Figure 3.7B). In liver, lower VC was seen in gulo-/- mice than in 
gulo+/+ controls (P<0.01) (Figure 3.7C).  
 
As expected, α-tocopherol levels in both cortex and liver were markedly decreased in all groups 
in this experiment, since all groups were on the VE-deficient diet (compare Figure 3.4D and E to 
Figure 3.7D and F). In addition to this lowering due to VE-deficient diets alone, α-tocopherol 
levels were significantly decreased in cortex (but not cerebellum and liver) in the 3 experimental 
groups compared to wild-type mice. In cortex, there was a main effect of both gulo and SVCT2 
genotypes (P<0.01), while in cerebellum there was only a main effect of gulo status (P<0.05). VE 
appears to be retained in the cerebellum slightly better than the other tissues with the gulo-/-
/SVCT2+/- group having less than a 50% decrease in content compared to the control mice 
(Figure 3.7D-F), however, overall levels were lower in the cerebellum than the cortex. Liver VE 
levels were often undetectable and no different between the groups (Figure 3.7F). 
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Measures of oxidative stress 
Cortex GSH levels in were increased in gulo-/-/SVCT2+/- mice deprived of VC compared to wild 
type and to SVCT2+/- mice (Figure 3.8A). There was a main effect of both gulo and SVCT2 
genotypes (P’s<0.01). A similar trend was observed in cerebellum with the highest levels in the 
gulo-/-/SVCT2+/- mice; however the interaction between Gulo X SVCT2 was not significant 
(P=0.070) (Figure 3.8B). The same effect was not observed in liver (Figure 3.8C). MDA levels 
were increased in cortex in all of the gulo-/- mice (P<0.01) mice after VC deprivation compared to 
the other two gulo+/+ groups (Figure 3.8D). There were no additional effects of SVCT2 genotype. 
MDA levels were not different in cerebellum among the genotypes, consistent with the slight 
changes in VE content. In liver, MDA was increased compared to wild type in the two VC-
deprived groups (Figure 3.8F).  There was a main effect of both gulo and SVCT2 (P’s<0.01). 
Together, these results show that VC deprivation, especially in the gulo-/-/SVCT2+/- mice, causes 
a modest increase in oxidative stress in cortex and liver.  
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Figure 3.7: Combined vitamin C & E deficiency decreases antioxidants in cortex, 
cerebellum and liver in gulo-/-/SVCT2+/-. 
Biochemical assessment included measurements of VC in cortex (A) cerebellum (B) and liver 
(C); VE in cortex (D) cerebellum (E) and liver (F).  
* Denotes a significant difference between gulo+/+ and gulo-/- groups (p<0.05) 
† Denotes a significant difference between SVCT2+/+ and SVCT2+/- groups (p<0.05) 
# Denotes a significant difference between two groups (p<0.05) 
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Figure 3.8: Combined vitamin C & E deficiency increases oxidative stress in cortex and 
liver in gulo-/-/SVCT2+/-. 
Oxidative stress assessment included measurements of glutathione in cortex (A) cerebellum (B) 
and liver (C); malondialdehyde in cortex (D) cerebellum (E) and liver (F). Displayed are group 
means ± standard errors of means.  
* Denotes a significant difference between gulo+/+ and gulo-/- groups (p<0.05) 
† Denotes a significant difference between SVCT2+/+ and SVCT2+/- groups (p<0.05) 
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DISCUSSION 
 
In Experiment 1, we investigated the effects of a combined VE & VC deficient diet on the 
neurobehavioral phenotype and oxidative stress measures in mice unable to synthesize their 
own VC. In contrast to guinea pigs, mice were more tolerant of combined VE and VC deprivation 
in terms of neurological deficits and survival. VE deficiency takes approximately 10 months to 
cause motor symptoms in mice compared to just 4-5 weeks in guinea pigs (114). In guinea pigs 
deprived of VE for only 2 weeks and VC for only 5-6 days, an ascending paralysis leading to 
death was observed (19), whereas as long as 10 months of VE deprivation in normal mice does 
not shorten stride or impair Rota-rod performance, despite an 80% decrease in VE levels in 
cortex and liver (115). Thus, it was not surprising that in the present study a VE-deficient diet 
alone for 16 weeks had no discernible effect on mouse gait or coordination, although it did 
decrease the latency to fall in the inverted screen test. 
 
VC deprivation alone in Experiment 1 decreased locomotor velocity and impaired inverted screen 
test performance. Normal habituation to the testing chamber, as evidenced by decreased 
exploration, was accentuated by VC deficiency alone in the current study. Although this change 
could be attributable to increased habituation in this group, it is more likely to reflect decreased 
voluntary locomotor activity due to physical weakness. Both VC-deprived groups showed poor 
performance on the Rota-rod. However, this difference was already apparent following the VE 
deprivation period, suggesting that it occurred by chance and was unrelated to the VC deficiency. 
Thus, although there were motor performance defects in this experiment, they did not confirm 
that the combined deficiency at this level of deprivation worsened strength or coordination 
compared to the single deficiencies. 
 
63 
In contrast, VE deprivation alone did increase both cortex and liver F2-isoprostanes, an 
established and sensitive marker of lipid peroxidation due to oxidative stress (116). Cortex F4-
neuroprostanes were also modestly increased by VE deprivation independently of VC status. For 
both markers, this could relate to the location of VE in the lipid bilayer of cellular membranes, 
where it can readily convert lipid peroxide radicals to the less damaging hydroperoxides. Other 
markers of oxidative stress, including MDA, and GSH were variably affected by dietary 
deprivation of either vitamin. Although these findings support the contention that VE deprivation 
in this manner causes a modest increase in brain lipid peroxidation, motor skills defects induced 
by short-term VC deprivation were not worsened by VE deficiency. VC deprivation consistently 
decreased VE content in both the cortex and liver. These results support those of in vitro studies 
showing that VC can recycle oxidized VE as α-tocopherol in lipid bilayers (108). Despite this role, 
VC deficiency in mice did not increase F2-iso- or F4-neuroprostanes, the most specific markers of 
lipid peroxidation (116), irrespective of VE depletion. 
 
Since deficiency of VC rather than VE was related to defects in motor performance in Experiment 
1, to accentuate this, a cellular deficit in VC was added to the systemic deficiency of both 
vitamins in Experiment 2 by crossing gulo-/- mice with SVCT2+/- mice. These mice on the doubly 
deficient diet had clear and consistent defects in all of the motor coordination skills tests. Only 
stride length and locomotor velocity remained unaffected. Decreased performance following VC 
deprivation on the horizontal beam and Rota-rod suggest that the defects were not simply due to 
decreased strength, but rather to a motor coordination defect reflecting neurologic impairment. 
Although an increase in anxiety could have confounded the coordination tests and accounted for 
the decrease in locomotor activity observed (117), data from the zero-maze test failed to show 
this, since the gulo-/-/SVCT2+/- mice spent a similar percentage of time in the closed area to the 
other groups. α-Tocopherol levels were substantially decreased in all mice in Experiment 2 
compared to the VE-supplemented groups in Experiment 1, so it is possible that this exacerbated 
64 
the motor skills defects. However, since VE deprivation did not affect motor performance 
independently of VC in Experiment 1, the contribution of VE deficiency to the observed motor 
skills defects would seem to be minimal.  
 
VC levels in cortex, cerebellum, and liver were decreased by about 50% in the gulo+/+/SVCT2+/- 
mice. This shows that this transporter is rate-limiting for VC uptake and content in both brain and 
liver. This is surprising (and unexplained) for liver, since these mice can synthesize their own VC 
in this organ. VC levels were more severely decreased in both brain areas and liver when the 
SVCT2+/- genotype was combined with the gulo-/- mice that were deprived of VC.  However, VC 
contents of cortex and liver, although low, were no different than in gulo-/- mice deprived of VC.  
Considering that the defects in motor performance observed might arise in the cerebellum, we 
measured levels of both vitamins, GSH, and MDA in cerebellum. Although levels of both vitamins 
were decreased as expected, both GSH and MDA were increased in cortex and not cerebellum, 
indicative of a greater oxidative stress in cortex. In previous studies with Gulo-/- mice deprived of 
VC, the cerebellum had better retention of VC and fewer changes in F2-isoprostane levels 
compared to the cortex (103). Data in the present study support the idea that the cerebellum is 
better protected against VC depletion and subsequent increased oxidative stress. 
 
The present results suggest that although VE deficiency for more than 16 weeks modestly 
increased lipid peroxidation in mouse brain and liver, it did not worsen the small and inconsistent 
motor skills deficits due to VC deficiency. Motor skills deficits became more extensive when 
cellular VC deficiency due to a decrease in cellular VC uptake was superimposed on VE 
deprivation and then followed by an acute deprivation of VC. Even though the mice in this study 
had no overt physical signs of scurvy beyond weight loss, it is likely that cellular deficiency of VC 
due to partial loss of the SVCT2 in the gulo-/-/SVCT2+/- mice hastened deficits in motor and 
coordination skills. The latter are likely to be early manifestations of acute scurvy. A recent study 
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of whole-body VC deficiency in zebrafish showed altered cellular energy metabolism 
homeostasis by activation of the purine nucleotide cycle (118). This suggests that VC deficiency 
may lead to inadequate energy production, which could also contribute to the behavioral deficits 
observed in this study.  Further studies will have to be performed to determine to role of energy 
homeostasis in this behavioral model. 
 
Although adult gulo-/- mice require significant systemic and cellular VC deficiency to manifest 
motor and coordination skills defects, developing mice appear to be more sensitive. In fact, gulo-/- 
dams that have been mated with gulo-/- sires have progeny that manifest similar motor skill 
defects as young adults, with increases in oxidative stress markers (103). In this study, all gulo-/- 
mice were derived from such matings. Although these mice may not be as capable as wild type 
mice would be in completing the motor skills tasks, the dietary and genetic modifications in adult 
gulo-/- mice in the present study clearly worsened any existing defects.  
   
In conclusion, in regard to our original question of whether there is a neurological phenotype that 
is associated with oxidative stress and/ or VC deficiency, our results show that a 16-week 
deficiency of VE modestly increased oxidative stress markers, but did not affect mouse motor 
skills or coordination. VC deficiency in addition to VE deficiency only minimally increased 
oxidative stress markers compared to the single deficiency model. However, VC deficiency did 
begin to impair motor and coordination skills, deficits in which become more evident when the 
cellular uptake of VC is decreased. A summary of the observed phenotypes respective of the 
genotypes is shown in Table 3.2. Whereas the latter may be an early manifestation of scurvy, its 
mechanism does not appear to be due to an increase in lipid peroxidation and remains to be 
determined.  
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CHAPTER IV 
 
VITAMIN C TRANSPORT AT THE NERVE TERMINAL 
 
Manuscript in Preparation 
 
INTRODUCTION 
 
Vitamin C (VC), an antioxidant not biosynthesized in humans, is an essential nutrient in the 
central nervous system (CNS) and neurons (49;119). Facilitated transport of VC across the 
plasma membrane of the neuron is a balance of two transport systems: uptake of VC inside the 
cell into the cytoplasm and efflux of VC outside the cell into the extracellular CSF. Dysregulation 
of VC concentrations on either side of the plasma membrane can lead to increased oxidative 
stress and abnormal neuronal development and function (53). Many cell models have been 
used to characterize the mechanisms for each transport system including neuron primary 
culture, neuroblastoma cell lines, human embryonic kidney (HEK) cells, and endothelial cells. 
However, how VC is transported in specialized regions within cells has received less attention. 
The most active region of the neuron is arguably the synapse, or nerve terminal, yet there are 
very few studies that investigate VC transport in this area. Neuronal pre-synaptic release sites 
are highly metabolically active and undergo a considerable amount of oxidative stress. 
Understanding the contribution for each transport system, uptake and efflux, at the nerve 
terminal is essential for fully appreciating the role of VC in neuronal health.  
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It is well established that the primary mechanism of VC uptake in the brain is mediated by the 
Sodium-dependent Vitamin C Transporter-type 2 (SVCT2) (53). Driven by the Na+ 
electrochemical gradient, the SVCT2 transports one molecule of VC along with 2 molecules of 
Na+ into the intercellular space (65). Mice that are homozygous for the SVCT2 knockout gene 
mutation have very low levels of VC in brain tissue despite the ability to synthesize the vitamin 
on their own (67). Equally as important as the function of the SVCT2 is its localization within the 
cell. In situ hybridization studies have shown that the SVCT2 mRNA is most neuronal cell types 
however, not glia (71). Studies with primary culture of mouse hippocampal neurons suggested 
that the SVCT2 was localized to the plasma membrane of the cell body and punctate areas in 
axons (120). Although these results suggest that the SVCT2 may reside in vesicular structures 
in neurons, they do not shed light on if the SVCT2 is present or functional specifically at the 
nerve terminals.  
 
Cellular models for VC efflux in brain include astrocytes (87;88) and SH-SY5Y neuroblastoma 
cells (83). The mechanisms for VC efflux in the brain are unclear but some appear to be 
mediated by channel proteins (82). Protein-mediated VC efflux from cells may occur 
spontaneously (temperature-dependent), within a heteroexchange system with other molecules 
or be glutamate-induced, which is observed when cells are stimulated with the excitatory 
neurotransmitter, glutamate. Concerning the latter, it is postulated that glutamate uptake causes 
cell swelling that in turn triggers volume-regulated anion channels (VRACs) to release 
osmolytes to prevent swelling-induced cell lysis. VC appears to be one of the substances 
released by VRACs in astrocytes (87) and neurons (83). This type of glutamate-induced VC 
efflux may be of physiologic relevance as glutamate is the most common excitatory 
neurotransmitter and comprises ~95% of the neuronal projections in cortex tissue (121). 
Furthermore, electrophysiologic studies in rats showed that glutamate-induced VC efflux was 
associated with neurobehavioral changes (96;122). Although most VC efflux mechanism studies 
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have been performed in astrocytes, it is unclear if similar mechanisms exist within neurons as 
well. This is especially relevant considering that most of the brain’s VC is concentrated in 
neurons. 
 
The physiologic link between how neuronal VC transport is regulated in culture and it is 
regulated in vivo may lie in the VC uptake and efflux systems maintained at the synapse. 
Synaptic sites are specialized regions that may have distinct mechanisms to regulate VC uptake 
and efflux to ensure proper neuronal function. Synaptosome preparations are an established 
model for studying synaptic mechanisms as these pinched off nerve terminals contain all the 
required protein machinery for synaptic function. VC uptake and efflux has been partially 
described in synaptosomes (123). These studies observed that VC could be taken up by 
synaptosomes when incubated with an excess of VC concentration. Furthermore, VC efflux 
from synaptosomes could occur spontaneously or following incubation with physiologic 
glutamate concentrations. However, the mechanisms in each of the systems have not yet been 
characterized. Therefore, the studies described in this paper investigate the SVCT2 expression 
and function in VC uptake in synaptosomes. Also, we investigated the potential role of VRACs 
in glutamate-induced VC efflux from synaptosomes. 
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RESULTS 
Neuronal SVCT2 localization 
To localize the SVCT2 in neurons with regard to known neuronal transporters, cultured mouse 
superior cervical ganglia (SCG) were immunostained with antibodies to the norepinephrine 
transporter (NET) (Figure 4.1A), the SVCT2 (Figure 4.1B), and to the vesicular monoamine 
transporter-2 (VMAT2) (Figure 1C). The rationale was that co-localization of the SVCT2 with 
either of these two transporters would help to identify the vesicles containing the SVCT2. The 
SVCT2 antibody stained fibers and particulate structures that corresponded in many areas with 
nerve fiber staining of the NET (Figure 4.1D). On the other hand, the SVCT2 and the VMAT2 
co-localized to particulate structures within nerve fibers (Figure 4.1E).     
 
The superior cervical ganglion has relatively large presynaptic boutons (~5 µm).  Using confocal 
fluorescence imaging, it is possible to take a section through the base of the bouton that forms 
the presynaptic side of the synaptic cleft (graphic representation, Figure 4.1F).  Since it shows 
proteins located in the presynaptic bouton membrane and in vesicles just below it, this approach 
can be used to determine whether proteins or transporter co-localize in this important region.  
When such a sectioned bouton was examined, all three transporters co-localized (inset to 
Figure 4.1D and E), suggesting that the SVCT2 co-localizes with both the norepinephrine and 
VMAT2 transporters in the presynaptic bouton membrane. This shows that the vesicles 
containing both transporters, as well as the VMAT2 transporter, have fused with the presynaptic 
membrane.   
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SVCT2 expression at the cortical pre-synaptic terminal  
To assess the location of SVCT2 protein within the nerve terminal we prepared synaptosomes 
from cortical tissue of male wild-type mice 4-6 months of age. Enriched synaptosome 
preparations were separated into three fractions: [1] cytosolic, which contains mostly detergent-
soluble cytosolic proteins including synaptic vesicles and peri-synaptic membrane fragments; [2] 
pre-synaptic, and [3] post-synaptic. The latter two fractions contain detergent-resistant 
membrane fragments of the active zone that are soluble at a pH of 6.0 and 8.0, respectively. 
The relative enrichment of synaptic proteins was compared to whole synaptosomes 
(unfractionated preparation) and assessed by Western immunoblots (Figure 4.2A and B). The 
cytosolic marker Glyceraldehyde 3-Phosphate Dehydrogenase, (GAPDH, Figure 4.2C), was 
enriched in the cytosolic fraction. VMAT2 (Figure 4.2D), was also found in the cytosolic fraction, 
but was more prominent in the pre-synaptic fraction. Two proteins located in the post-synaptic 
terminal, N-methyl-D-aspartate Receptor, (NMDAR1, Figure 4.2E) and Postsynaptic Density 
Protein 95 (PSD-95, Figure 4.2F) were enriched in the post-synaptic fraction. These markers 
confirmed that the fractionation procedure enriches sub-cellular proteins found in these parts of 
the synapse. Under these conditions, SVCT2 was predominantly enriched in the pre-synaptic 
fraction (Figure 4.2G), suggesting that SVCT2 is indeed localized at the synapse, at the pre-
synaptic terminal specifically. 
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Figure 4.2: SVCT2 is localized in pre-synaptic fractions. 
[A] Western immunoblots of cortical synaptosome preparations and fractionated samples. 
Samples containing 5µg of protein were subjected to SDS-PAGE. Samples were probed for 
cytosolic protein, Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH); pre-synaptic protein, 
Vesicular Monoamine Transporter (VMAT2); and two post-synaptic proteins, N-methyl-D-
aspartate Receptor (NMDAR1) and Postsynaptic Density Protein 95 (PSD-95). 
[B] Samples containing 30µg of protein were subjected to SDS-PAGE under same fractionation 
conditions and probed for SVCT2. Bands in each lane were normalized by G-protein β subunit 
expression and compared to the initial crude synaptosome preparation (first lane). 
Quantification of [C] GAPDH, [D] VMAT2, [E] NMDAR1, [F] PSD-95 and [G] SVCT2 are 
represented as the mean ± SEM of two different experiments.  
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SVCT2 function in crude cortical synaptosomes  
Net VC uptake 
To determine if SVCT2 functions at the nerve terminal, we performed experiments to 
characterize net VC uptake. We found that crude synaptosomes contained endogenous VC at 
~80 nmol/g (Figure 4.3A). Upon incubation for 30 min with 250 µM unlabeled VC, a two-fold 
increase in VC content was observed (Figure 4.3A). Two known SVCT2 inhibitors, 
sulfinpyrazone and phloretin prevented this uptake (Figure 4.3A). Similar results were observed 
in studies using radiolabeled 14C-VC, which also showed net uptake of 14C-VC uptake at ~80-
100 nmol/g when incubated for 30 min (Figure 4.3B). Radiolabeled VC uptake was also 
inhibited by sulfinpyrazone and phloretin, as well as by replacement of sodium with choline. It 
has been shown that the oxidized form of VC, dehydroascorbic acid (DHA) can be transported 
on the GLUTs in neurons and astrocytes (54). However, the GLUT transporter competitive 
inhibitor, 3-0-methylglucose at a concentration that will substantially compete for 
dehydroascorbic acid, did not affect 14C-VC uptake. This indicated that 14C-VC uptake was 
independent of GLUT function. 
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Figure 4.3: Net Vitamin C uptake in cortical crude synaptosomes. 
[A] Crude synaptosomes were incubated for 30 min without (control) and with 250 µM VC only 
or 250 µM VC and 10 min pre-incubation with 1 mM sulfinpyrazone and/or 0.1 mM phloretin. 
[B] Crude synaptosomes were pre-incubated for 10 minutes with 1 mM sulfinpyrazone, 0.1 mM 
phloretin, sodium-free KRH buffer, 1mM unlabeled VC, or 40 mM 3-0-methylglucose before the 
addition of 14C-VC (0.05 µCi, 7 µM) and further incubated for 30 minutes. Background 14C-VC 
signal was determined by assessing the signal detected after lysing synaptosomes. This 
amount was then subtracted from all of the readings. 
[C] Crude synaptosomes were incubated with 14C-VC (0.05µCi, 7µM) for different periods of 
time or [D] concentration for 10 minutes. The calculated Km was ~12-15 µM. The results 
represent the mean ± SEM of a representative experiment performed in duplicate. *P<0.05  
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Kinetic characterization of VC uptake 
To determine if the kinetic properties of VC uptake in synaptosomes were similar to those 
expected if transport occurred via SVCT2, time and concentration curves were performed using 
radiolabeled VC. The uptake of 14C-VC was linear for about 20 min (Figure 3C). Using an 
incubation time in the linear phase of uptake (10 min), uptake was saturable the and apparent 
Km and Vmax of 18.31 ± 4.7 µM and 277 ± 28.15 nmol/g/30 min, respectively.  These data 
suggest that the VC uptake in synaptosomes is consistent with SVCT2 function.  
 
Net VC efflux out of cortical synaptosomes  
VC transport is a balance between uptake and efflux. In order to assess the contribution of VC 
movement out of synaptosomes, a series of efflux studies were performed to observe the 
release of endogenous VC from non-loaded synaptosomes over time. Two types of VC efflux 
mechanisms were studied: spontaneous and glutamate-induced. Spontaneous endogenous VC 
efflux was measured since net uptake would depend on efflux occurring at 37°C. We also 
assessed glutamate-induced VC efflux because of its physiologic relevance.  
Temperature dependence of spontaneous VC efflux 
No VC efflux was observed at 4°C, whereas at 37°C, the endogenous VC concentration steadily 
decreased over time and after 30 min had decreased to ~80 – 100 nmol/g, comparable to the 
uptake experiments over the similar time frame (Figure 4.4A). To determine the contribution of 
SVCT2 to VC efflux, synaptosomes were incubated with the SVCT2 inhibitors, phloretin and 
sulfinpyrazone, for 30 min at 37°C. The presence of these inhibitors did not inhibit efflux but 
rather enhanced efflux by 25% and 50%, respectively (Figure 4.4C and E). This is likely due to 
the decrease in net VC uptake caused by the inhibition of the SVCT2, resulting in an apparent 
increase of net efflux. This suggests that the SVCT2 is not responsible for VC efflux, but that 
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influx does play a role in VC homeostasis in the synaptosome. To ensure that this efflux was not 
due to a compromise in the integrity of the membrane, synaptosomes were pre-loaded with 
Fura RedTM dye for 30 min at 37°C. The synaptosomes were centrifuged and re-suspended in 
buffer. A subsequent time course experiment assessed efflux of the water-soluble intracellular 
dye over 30 min at 37°C. There was minimal leakage of the dye, suggesting that synaptosome 
integrity is maintained during the course of this type of experiment (Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Synaptosome membrane integrity is maintained during the course of 
experiment.  
Synaptosomes were pre-loaded with Fura Red dye for 30 minutes at 37°C and then incubated 
at 37°C with or without 5% Triton X-100 (Sigma T-9284) or 60% MeOH. The results represent 
the mean ± SEM, N=4. 
 
  
Time (mins)
Fu
ra
 R
ed
 C
on
te
nt
(%
 o
f 3
7°
 In
iti
al
)
0 20 40 60
0
25
50
75
100
37°
Triton X or MeOH
78 
 
Figure 4.4: Spontaneous Vitamin C Efflux. 
Time course of spontaneous VC efflux. [A] Relative VC content over 30 min at 4°C (closed 
circles) and 37°C (open circles). The initial synaptosomal VC concentration was ~250-300 
nmol/g. [B] Logarithmic transformation of data in panel A where (*) denotes a significant 
difference between the slopes of the two lines. [C] Relative VC content over 30mins of efflux at 
37°C with (open circles) and without (closed circles) 1 mM sulfinpyrazone [D] Logarithmic 
transformation of data in panel C where (*) denotes a significant difference between the slopes 
of the two lines. [E] Relative VC content over 30mins of efflux at 37°C with (open circles) and 
without (closed circles) 100 µM phloretin [F] Logarithmic transformation of data in panel C where 
(*) denotes a significant difference between the slopes of the two lines. 
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Hypotonic-Induced VC Efflux 
To determine the effect of osmolality on VC efflux in synaptosomes, preparations were 
incubated in hypotonic conditions and VC content was assessed after 5 min. Figure 4.5 shows 
VC content of synaptosomes in isotonic buffer (300 mOsm), hypotonic Na+ control buffer (300 
mOsm, with choline replacement), and hypotonic buffer (200 mOsm). VC content decreased 
~50% after incubation with hypotonic buffer alone. This decrease was completely eliminated in 
the presence of 1 mM DIDS, an ion channel inhibitor known to inhibit VRAC (124). These data 
suggest that VC efflux from synaptosomes is enhanced by hypotonicity independent of the 
sodium concentration and mediated by an anion channel. 
 
 
 
Figure 4.6: Hypotonic solution-induced vitamin C efflux.  
Crude synaptosomes were incubated in buffers of various tonicities and sodium content for 5 
min and residual synaptosomal VC content was measured after 5 min at 37°C. Samples shown 
by the last bar were pre-incubated with 1 mM DIDS for 5 min at 37°C before the efflux 
experiment. N = 2, with p < 0.05 compared to other bars. 
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Glutamate-Induced VC Efflux  
To determine the mechanism for glutamate-induced VC efflux in synaptosomes, preparations 
were incubated with increasing concentrations of glutamate (Figure 4.6). A decrease of about 
50% was observed when 200 µM glutamate was incubated with the synaptosomes for 30 min. 
Therefore, this concentration was chosen for subsequent experiments. Time course 
experiments confirmed that there was a significant increase in VC efflux at 37°C in the presence 
of glutamate (200 µM) resulting in an additional 15% decrease in VC content by the end of 30 
min compared to 37° at 30min (Figure 4.7A and B). Pre-treatment of synaptosomes with 1 mM 
DIDS before the addition of 200 µM glutamate significantly decreased VC-efflux compared to 
200 µM glutamate alone (Figure 4.7C and D). These data suggest that glutamate-induced VC 
efflux in cortical synaptosomes may occur on volume-regulated anion channels, as it is sensitive 
to the VRAC inhibitor, DIDS. As a control for the DIDS effect on basal (spontaneous) VC efflux, 
synaptosomes were incubated with DIDS (1mM) for 30 min at 37°C. The presence of DIDS 
failed to either inhibit or enhance efflux.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Glutamate concentration curve.  
Vitamin C content of synaptosomes incubated with increasing concentrations of glutamate (0-
400 µM), expressed as a fraction of control. N=3. 
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Figure 4.8: Glutamate Induced Vitamin C Efflux. 
Time course of glutamate-induced VC efflux. [A] Relative VC content over 30 minutes 37°C with 
(open circles) and without (closed circles) 200 µM glutamate. [B] Logarithmic transformation of 
data in panel A where (*) denotes a significant difference between the slopes of the two lines. 
[C] Relative VC content over 30 minutes 37°C with (open circles) and without (closed circles) 
1mM DIDS. [D] Logarithmic transformation of data in panel C where (*) denotes a significant 
difference between the slopes of the two lines. [E] Relative VC content over 30 minutes 37°C 
with (open circles) and without (closed circles) 1mM DIDS. [F] Logarithmic transformation of 
data in panel C  
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DISCUSSION  
Neuronal VC concentration depends on VC transport across the plasma membrane is critical for 
proper neuronal function. VC is highly concentrated in neurons compared to surrounding glia 
cells that lack SVCT2 in vivo (71). VC transport has been extensively studied in several cell 
lines however, the physiologic link between how neuronal VC transport is regulated in culture 
and it is regulated in vivo may lie in the VC uptake and efflux systems maintained at the 
synapse. Using synaptosomes as a model to investigate VC regulation at the nerve terminal, 
this paper describes the SVCT2 expression and function in VC uptake and also the potential 
role of VRACs in glutamate-induced VC efflux. 
First, we determined that the SVCT2 is expressed at the nerve terminal of superior cervical 
ganglia cells in the peripheral nervous system. Immunostaining of these cells showed 
colocalization of the SVCT2 with both the NET and VMAT2 at the presynaptic bouton. This data 
is not the first to show localization of the SVCT2 in catecholamine excreting cells. SVCT2 is also 
present in adrenal chromaffin cells, and likely accounts for their high intra-vesicular VC 
concentrations (125). Furthermore, Bornstein et al. (126) showed that adrenal chromaffin cell 
function is severely impaired and had morphological abnormalities in SVCT2 null mice. Based 
what is known about VMAT2 localization (127), these results may support the notion that the 
SVCT2 is carried in regulated dense core vesicles that are stored at presynaptic release sites. 
In order to determine if the SVCT2 was expressed in nerve terminals in the CNS, enriched 
cortical synaptosome preparations were used. Uptake of VC in primary culture neurons is 
dependent on SVCT2 expression (120). Thus it was not surprising that SVCT2 was present in 
cortical synaptosome preparations. We determined the SVCT2 expression at the nerve terminal 
to be localized primarily in the presynaptic fraction some expression in the cytosolic fraction. 
This may indeed imply SVCT2 localization in several distinct compartments, as the cytosolic 
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fraction contains proteins that are localized peri-synaptically and in membrane-bound organelles 
including synaptic vesicles and mitochondria. It has recently been shown that HEK-293 
mitochondria express SVCT2 (128). 
 
In order to determine if the SVCT2 was functional at nerve terminals in the CNS, crude cortical 
synaptosome preparations were used. While the role of SVCT2 has been established in whole 
neurons, this study is the first to characterize its function at the nerve terminal. SVCT2 may 
function to reuptake VC after depolarization at the pre-synaptic terminal and actively transport 
VC inside the secretory vesicles in the cytosolic compartment. To determine if VC uptake in 
synaptosomes was consistent with SVCT2 function we performed uptake studies. Consistent 
with previous studies, VC uptake plateaued and saturated over time and concentration, 
characteristic of facilitated transport on a protein transporter rather than a channel. Kinetic 
analysis of VC uptake in synaptosomes showed that the apparent Km was similar to that of the 
SVCT2 in neuronal cell systems. Furthermore, known SVCT2 inhibitors, sulfinpyrazone and 
phloretin inhibited VC uptake in synaptosomes. Therefore, SVCT2 likely mediates VC transport 
at the nerve terminal. 
 
Extracellular VC concentration in the CNS is maintained homeostatically (129). Meile and 
Fillenz reported that extracellular VC is regulated homeostatically in vivo, in awake, behaving 
animals (130). In these studies, 100 –1000 µM VC was perfused through a microdialysis probe, 
with voltammetric detection of extracellular VC in the tissue adjacent to the probe. 
Concentrations that were lower than 400 µM caused extracellular VC to fall, whereas higher 
concentrations caused an increase in extracellular VC. After each perturbation, extracellular VC 
recovered within a few minutes, which demonstrates homeostasis. Homeostatic regulation of 
extracellular VC suggests that the extracellular compartment of brain tissue might be an 
important site of action for VC (71). To determine role of the SVCT2 in VC efflux, we 
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investigated spontaneous efflux from synaptosomes. Spontaneous VC efflux occurred at 37°C 
but not at 4°C. This is consistent with results of previous studies of VC efflux from rat 
synaptosomes (123). While SVCT2 appeared to mediate VC uptake into synaptosomes, it 
opposed efflux, since the latter was increased by its inhibition. Spontaneous VC efflux most 
likely does not involve SVCT2. Additional studies will have to be performed to determine the 
mechanism of spontaneous VC efflux.  
 
There have been several papers published recently that have emphasized VC release in 
conjunction with a number of neurotransmitters including glutamate (131-133). Glutamate-
induced VC efflux has been studied in astrocytes but the proteins mediating this process in 
neurons and synaptosome model are unknown. However, there is growing evidence that 
suggests that VRAC might be involved in glutamate-induced VC efflux particularly after cell 
swelling in astrocytes (88). We hypothesize that a similar process is happening at the nerve 
terminal and that VC efflux was occurring on VRACs in synaptosomes as well.  
 
Our data shows glutamate indeed stimulates VC efflux and that co-incubation with VRAC 
inhibitor, DIDS, attenuates glutamate-induced VC efflux. These data suggest DIDS-sensitive 
VRACs could mediate glutamate-induced VC efflux at the nerve terminal. Recent studies by 
Lane and Lawen (133) demonstrated that the effects of glutamate on VC efflux in astrocytes are 
not due to the isolated activation of iGluRs, or mGluRs, since the release of VC from astrocytes 
cannot be emulated by agonists that are selective for NMDA and AMPA iGluRs or group 1 
mGluRs. It is unclear if group II or III mGluRs are involved. This supports the concept that 
glutamate uptake is essential for VC efflux. 
 
One caveat to this study is that DIDS in a non-specific anion channel inhibitor that could inhibit 
glutamate uptake and thus subsequently VC efflux (134;135)
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effect of osmolality on VC efflux. To determine if the change in osmolality associated with the 
adding glutamate could be responsible for VC efflux, we assessed VC efflux in a hypotonic 
buffer. Hypotonicity-induced VC efflux indeed occurred, and was attenuated with DIDS 
suggesting that DIDS-sensitive VRACs could mediate VC efflux due to swelling. This also 
indicates a glutamate-independent inhibition of VC efflux by DIDS, and DIDS had no effect on 
spontaneous VC efflux. This data also indicates that DIDS influence on VC efflux is independent 
of glutamate uptake.  
 
In conclusion, we were able to provide evidence that SVCT2 protein is expressed predominately 
at the pre-synaptic terminal and functions to mediate VC uptake at the synapse. VC efflux from 
synaptosomes occurs in several conditions including spontaneous induction and glutamate-
induction. While the mechanisms for VC efflux are not completely clear, our studies suggest that 
VRACs are likely to have a contribution in glutamate-induced VC efflux. Additional studies will 
need to be performed to determine if other types of VC efflux, including depolarization-induced 
VC efflux occurs via similar processes (Figure 4.8). 
 
Understanding transport mechanisms for VC are crucial to understanding VC’s role at the 
synapse. Currently, lack of molecular identification of VRACs is a significant drawback in the 
assessment of their role in VC efflux. Furthermore, as putative VRACs contribution accounts for 
less than 50% of the VC efflux by many of the cells tested, including hepatocyte-like Hep-G2 
cells (84), SH-SY5Y neuroblastoma cells (83), and K562 cells (86), other release pathways are 
probably significant contributors. Further studies will have to be performed in order to 
characterize proteins involved in VC efflux.  
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Figure 4.9: Model of Vitamin C Uptake and Efflux at a Representative Nerve Terminal. 
VC transport is a balance between uptake and efflux. SVCT2 protein is expressed 
predominately at the pre-synaptic terminal and functions to mediate VC uptake at the synapse. 
VC efflux occurs in several conditions including (1) spontaneous induction, (2) glutamate-
induction and (3) depolarization-induction. There are several proteins that could mediate 
glutamate uptake in neurons including EAAC1 and GLAST (136). glutamate-induced VC efflux 
is associated with synaptosome swelling which trigger VC permeable DIDS-sensitive VRACs. 
Depolarization induces VC efflux by exocytosis of VC contain secretory vesicles. 
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SUMMARY AND CONCLUSIONS 
 
BACKGROUND 
We know a great deal about VC, but its function is as elusive as it is ubiquitous. The full picture 
of VC’s contribution to human health has yet to be seen. There has always been a sense of 
urgency to understand this molecule and with its discovery, the dogma was born: the body needs 
just enough VC to prevent deficiency or scurvy to be healthy. Albert Szent-Gyorgyi, however, 
championed the notion that there was a wide gap between scurvy and full health. Linus Pauling, 
a renowned leader in the study of VC function, postulated that animals capable of synthesizing 
VC made more than the amount required for optimum health because of the burden of metabolic 
processes. Furthermore, these amounts could be used to calculate the ideal amount for human 
consumption, and suggested the RDA for VC should be 250 – 4000 mg per day based on his 
observation that many population groups were not ingesting enough VC for full saturation of 
tissues (137). Mark Levine, the leading expert on optimal VC concentration in tissues, may not 
support VC intakes as high as Pauling, but nonetheless has reinforced the idea of tissue 
saturation by assessing the pharmacokinetics of VC absorption. Currently, the paradigm is 
beginning to shift to appreciate the importance of adequate VC concentrations for optimal health 
as well as the necessity for a more comprehensive understanding of how VC impacts normal 
physiology (138). To date, we have determined VC’s antioxidant and non-antioxidant roles in 
processes that vary widely from the integrity of tissue structure (collagen), to regulation of DNA 
function and transcription, and to the essential defense from ROS and RNS in virtually every cell 
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type. In this document I have initiated an investigation of a mechanism that couples the 
regulation of VC transport with motor coordination and proper neuronal function.   
 
COMBINED VITAMIN C AND E DEFICIENCY ALONG WITH DECREASED SVCT2 
EXPRESSION CAUSES MOTOR COORDINATION DEFECTS  
 
First, it is debatable if the RDA of VC is sufficient for optimal health. Although fully developed 
scurvy is not as prevalent in the US, VC deficiency and “marginal status,” defined as less than 
(20%) and (10%) of RDA value, respectively, is a condition that effects up to 30% of the US 
population (113;139). To further complicate the problem, populations that are deficient in VC are 
also likely to have a diet that is deficient in other vitamins, low on fruits vegetables and high in fat 
and sucrose. These caveats are known to influence the bioavailability and subsequently the 
regulation of VC. In order to elucidate how these conditions of low VC levels affect neuronal 
health it is important to understand how VC is regulated in the brain.  
 
The role of VC as an antioxidant has received more attention than the other biological functions 
of VC. Oxidative stress has been implicated in many neurodegenerative diseases. However, the 
mechanisms of how dietary deficiencies of antioxidant contribute to pathology of these diseases 
are not fully understood. Therefore, in specific aim 1, we initially evaluated if oxidative stress due 
to combined VC and VE deficiency had a neurobehavioral phenotype. A pilot study was 
conducted to determine the optimal parameters for adapting the well-known guinea pig model to 
mice. We employed the use the Gulo-/- mouse model because of its physiologic relevance, as 
these mice, like humans, were dependent on dietary VC. Results from the pilot study indicated 
the optimal time to assess behavior was after 4 months of VE deprivation followed by 3 weeks of 
VC deprivation. At this time, mice are asymptomatic because scurvy has not fully developed 
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despite the 80% and 75% decrease in VE and VC respectively. These conditions were used in 
subsequent studies to determine the individual contribution of each vitamin deficiency and also 
the effect of the combined vitamin deficiencies to oxidative stress. 
 
In a second study, we expanded the biochemical and behavioral assessment of the experimental 
mice to include VC, VE, GSH and MDA in cortex, cerebellum and liver tissues as well and 
anxiety test. We concluded that the combined vitamin deficiency resulted in only a modest 
increase of oxidative stress, particularly lipid-peroxidation. However, as observed in our pilot 
study, there were no major alterations in behavior. It was not until SVCT2 protein expression was 
decreased that a more extensive motor skills deficit was observed. The model using Gulo-/-
/SVTC2+/- was intended to further decrease cellular VC by limiting uptake of the vitamin. 
However, this was not observed, as overall VC concentrations in the cortex and cerebellum were 
not drastically different. Furthermore, oxidative stress, as measured by MDA, was not markedly 
increased. Nonetheless, the combined vitamin deficiency produced a profound effect on the 
neurologic phenotype in these mice that included motor-coordination defects.   
 
Therefore, in regard to our original question of whether there is a neurological phenotype that is 
associated with oxidative stress and/ or VC deficiency, our results show that a 16-week 
deficiency of VE modestly increased oxidative stress markers, but did not affect mouse motor 
skills or coordination. VC deficiency in addition to VE deficiency only minimally increased 
oxidative stress markers compared to the single deficiency model. However, VC deficiency alone 
did begin to impair motor and coordination skills, deficits in which become more evident when the 
cellular uptake of VC is decreased. The mechanism does not appear to be due to an increase in 
lipid peroxidation and remains to be determined. 
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Possible causes of neurobehavioral changes in cellular vitamin C deficiency. 
Acute generalized (whole body) scurvy 
Although the mice in this study had no overt physical signs of scurvy beyond weight loss, it is 
clear that cellular deficiency of VC due to partial loss of the SVCT2 in the gulo-/-/SVCT2+/- mice 
hastened deficits in motor and coordination skills. The latter could be early manifestations of 
acute or latent scurvy characterized by fatigue, dull aches and irritability. This may explain poor 
performance on behavioral tasks. Therefore, even if the deficits are due to latent scurvy, this 
provides evidence that VC deficiencies associated with the earliest stages of scurvy could have 
cognitive or neurobehavioral effects. In the human population, symptoms of acute scurvy are 
similar, but there are very few studies that look at the effect of low VC levels on motor-
coordination (2;140). Indeed scurvy does cause severe lassitude (lack of physical or mental 
energy) and asthenia (weakness) in humans, however the terminal symptomatology of scurvy is 
mostly due to vessel and organ rupture because of collagen defects rather than neurological 
deficits. This is likely because VC is retained in the brain even under severe VC depletion 
(78;141). As noted earlier, such retention in the brain may suggest important neural function. 
Although the disease has been associated with paraparesis (partial paralysis of the lower limbs) 
in humans, death appears to be due more to complications of systemic collagen dysfunction and 
not to a clear neurologic syndrome (44).  
Imbalance in energy homeostasis  
Kirkwood, et al. (118) used the zebrafish model to investigate the role of VC in energy 
homeostasis. This model is useful, as it does not require genetic manipulation because zebrafish, 
like humans, cannot make VC. They concluded that whole-body VC deficiency in zebrafish 
altered cellular energy-metabolism homeostasis by activation of the purine nucleotide cycle. 
Their studies showed that VC decreased adenosine monophosphate (AMP) levels by elevating 
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AMP deaminase (AMPD) activity, however it is unclear if recruitment of the AMP receptor is 
altered. This suggests that VC deficiency may lead to inadequate energy production, which could 
also contribute to the behavioral deficits observed in our studies in specific aim 1. In a follow-up 
(142) study by the same group, it was shown that VE deficiency caused an increase in oxidative 
stress that led to depletion of VC. Subsequent damage to the muscle fibers resulted in impaired 
muscle function. While we do not think that the oxidative stress in the combined VC and VE 
deficient Gulo-/- mouse model was severe enough to cause extensive muscle damage in the 
short time-span of our experiments, further studies will have to be performed to determine the 
role of VC in energy homeostasis, Furthermore, any effects of VC on the activity of AMPK should 
be investigated, as it may have a broader impact on cellular energy metabolism. 
 
DYSREGULATION OF VITAMIN C UPTAKE VIA ALTERED NEURONAL SVCT2 
EXPRESSION IMPAIRS NEURONAL FUNCTION.  
 
In the studies for specific aim 1, it appeared that regulation of VC uptake, not necessarily VC 
concentration alone, had a substantial contribution to behavior. This was evidenced by the fact 
that the Gulo-/-/SVCT2+/+ group and the Gulo-/-/SVCT2+/- group on the same combined VC- and 
VE-deficient diet had decidedly different behavioral phenotypes, despite the fact that VC 
concentrations in cortex or cerebellum tissue were not significantly different. There is a growing 
body of evidence that suggests that not only VC concentration matters, but also local, acute 
transport of VC in and out of neurons affects their function (82). Limitations of the studies 
performed in specific aim 1 include not being able to determine how VC is compartmentalized 
within the brain tissues. Thus, localized severe VC deficiencies in crucial brain areas or even 
cells (e.g., Purkinje cerebellar neurons) could have caused the motor and behavioral changes 
observed. This caveat should also be considered at the sub-cellular level for what is arguably the 
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most important region for neural signal propagation, the nerve terminal. Decreases in synaptic 
VC transport by the SVCT2 protein could lead to acute impaired neuronal function. Evidence for 
this possibility derives from functional SVCT2 and electrophysiology studies in hippocampal 
neuronal culture. Qiu et al. in the May lab (120) showed that neurons from SVCT2-/- mice 
displayed miniature excitatory post-synaptic currents (mEPSC) that were smaller in amplitude 
and occurred less frequently compared to wild-type neurons, suggesting that SVCT2 activity is 
required for normal glutamatergic function. This paralleled a decrease in the number of dendritic 
branches. Furthermore, it was observed that SVCT2-/- neurons expressed fewer GluR1 clusters, 
indicating that the transporter is required for normal development of glutamatergic function of 
cultured hippocampal neurons. These changes, coupled with the aforementioned localization of 
the SVCT2 in the presynaptic bouton in superior cervical ganglion neurons of the peripheral 
nervous system, led me to investigate whether SVCT2 was expressed and functional at nerve 
terminals in the central nervous system (CNS) in specific aim 2.  
 
TRANSPORT OF VITAMIN C IS TIGHTLY REGULATED AT THE NERVE TERMINAL IN THE 
CNS 
There are no studies to date that have investigated the mechanisms of VC transport at the 
neuronal synapse in the CNS. Therefore, the goal of specific aim 2 was to determine how VC 
transport was regulated at the cortical nerve terminal. We employed the use of synaptosomes, 
which have long served as a model of the nerve terminal (143;144). These pinched off nerve 
endings are fully functional and can be used to investigate transport of molecules at the nerve 
terminal. It has been established that VC is transported in and out of synaptosomes (123), but 
how this occurred has not been fully characterized.  
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Although it is well established that the SVCT2 was the primary mediator of VC uptake in 
neurons (53), the studies described in this document were the first study to demonstrated that 
SVCT2 was indeed present in pre-synaptic fraction of synaptosomal preparations. With a series 
of uptake studies with inhibitors we were able to characterize VC uptake and conclude that it is 
likely mediated by SVCT2. The inhibitors sulfinpyrazone and phloretin, while not specific for 
SVCT2, are well-documented inhibitors of VC uptake (82). The fact that the transporter is 
present and functional in this specialized region of the neuron is supporting evidence for 
compartmentalized non-antioxidant roles of VC within the neuron.  
 
VC efflux has been characterized in many cell types, as noted previously. However, the proteins 
that mediate VC transport out of most cells are still unknown. With a series of inhibitor studies in 
hepatocytes, Upston, et al. (84) were able to distinguish proteins that mediated DHA uptake 
from those that mediated VC release, but the latter were not identified. In the brain, it has long 
been established by the studies of Rebec and others that VC uptake and efflux is highly 
correlated with changes in behavior (52), For example, the level of behavioral activation in 
rodents is correlated with the level of striatal VC release (145). These changes were thought to 
be mediated by the striatal glutamatergic system (146). In vivo studies using voltammetric 
electrode recordings showed that extracellular VC signals were directly related to the amounts 
of microinjected glutamate. This signal was dependent on glutamate reuptake as it was 
eliminated in the presence of inhibitors of glutamate uptake, homocysteic acid and d,l-threo-β-
hydroxy-aspartic acid (147). 
 
At the cellular level, studies to elucidate the mechanisms of VC efflux have been carried out 
mainly in primary cultures of rat astrocytes. Wilson, et al. (87) hypothesized that glutamate 
uptake triggered the release of VC. Using primary cultures of rat cerebral astrocytes they 
observed that extracellular glutamate increased VC efflux. Hypertonic media inhibited this efflux. 
94 
Wilson’s group did not find evidence that glutamate-ascorbate heteroexchange mechanism was 
involved, since levels of intracellular VC did not affect glutamate uptake. They proposed rather 
that the tonicity of the extracellular fluid was one determinant of VC efflux. The anion channel 
inhibitors 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS) inhibited both Na+-dependent 
glutamate uptake and VC efflux. These studies were able to distinguish between mediating 
proteins as two other inhibitors of volume-sensitive organic anion channels (1,9-dideoxyforskolin 
and 5-nitro-2-(3-phenylpropylamino) benzoic acid) (NPPB) did not slow glutamate uptake but 
prevented stimulation of VC efflux (87). This prompted them to propose that glutamate causes 
cell swelling, which then allows VC efflux on volume-sensitive or –regulated anion channels.  
 
Using these experiments as a guide, I hypothesized that a similar mechanism could mediate 
efflux in synaptosomes. Our studies showed that indeed spontaneous and glutamate-induced 
VC efflux occurred in synaptosomes. In our spontaneous studies we observed that net VC 
transport was a combination of uptake and efflux. SVCT2 inhibition had a greater concentration-
dependence on apparent VC efflux then we originally expected, as a drastic decrease in VC 
content was observed. While the mechanism behind this type of efflux was not fully 
characterized, the inhibitor study showed that SVCT2 largely mediates uptake and does not 
function bi-directionally. Furthermore, VRACs may not contribute to spontaneous efflux, as 
incubation with DIDS did not affect VC concentrations during the time course experiments.  
 
My studies of glutamate-induced VC efflux suggest that VRACs may mediate efflux as DIDS did 
inhibit decreases in VC levels. Furthermore, this effect was recapitulated with hypotonic 
solutions without glutamate. However, future studies should include the use of additional 
inhibitors to gain a clearer understanding of the types of channels involved in efflux. For 
example, the inhibitor IAA-94 targets different chloride ion channels (CLIC) that may contribute 
to VC efflux. Synaptosomes appeared to be more sensitive to the use of inhibitor solvents such 
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as DMSO and ethanol as even low concentrations seem to lyse the synaptosomes and preclude 
uptake studies with NPPB and niflumic acid, which target ClC-1 and ClC-2, respectively. The 
next steps for the continuation of the work will include inhibitor studies with 1,9-dideoxyforskolin 
as well as studies leading to identification of VRAC proteins involved. Currently, none of the 
presumed VRACs have been identified and therefore there is no antibody known to be specific 
for these channels. Once identified, it will be necessary to determine using siRNA and knockout 
experiments whether the channel(s) in question in fact mediate VC efflux and under what 
conditions, including changes in osmolality and glutamate stimulation. 
 
What implications does this research have for in vivo models? 
 The fact that spontaneous VC efflux appeared to level off after ~50% decrease in VC suggests 
that intracellular VC levels may regulate its transport. In vivo models have shown changes in 
SVCT2 protein levels in response to intracellular VC concentration in brain tissue (77). In an 
attempt to determine whether and how intracellular VC levels may alter SVCT2 protein 
expression at the nerve terminal, I compared SVCT2 expression in enriched synaptosome 
fractions prepared from Gulo-/- mice on VC deficient diet with that of Gulo-/- that were 
supplemented with VC. However, there was no change in protein levels in any of the fractions. 
Furthermore, I was not able to detect a consist increase in VC uptake in crude synaptosome 
preparations from these mice. Although, I did not observe an effect of intracellular VC 
concentration by assessing SVCT2 uptake in Gulo-/- mice with or without VC supplementations, 
an interesting assessment would be the comparison of VC uptake in synaptosomes prepared 
from mice with different protein expression levels of SVCT2 (SVCT2+/- and SVCT2-Transgenic).  
 
This research can impact human health by providing insight on how VC is regulated in the brain, 
particularly the cortical neuron. Understanding how this antioxidant’s contributes to the bigger 
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picture of brain health and function is crucial for the advancement of therapeutic options that 
can combat specific forms of oxidative stress that are implicated in neurodegeneration.  
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APPENDIX 
 
PILOT STUDY BIOCHEMICAL AND BEHAVIOR ASSESMENT 
Wildtype (Gulo+/+; SVCT2+/+) mice were subject to 0, 2, 4 or 6 months of vitmain E deprivation 
followed by 3 weeks of vitamin C deprivation. 
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